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III   ABSTRACT 
 
Alcoholic liver disease (ALD) is a well recognized and growing health problem 
worldwide. ALD advances from fatty liver to inflammation, necrosis, fibrosis and 
cirrhosis. There is accumulating evidence that the innate immune system is involved 
in alcoholic liver injury. Within the innate and acquired immune systems, the 
complement system participates in inflammatory reactions and in the elimination of 
invading foreign, as well as endogenous apoptotic or injured cells. The present study 
aimed at evaluating the role of the complement system in the development of 
alcoholic liver injury. 
 
First, in order to study the effects of chronic ethanol intake on the complement 
system, the deposition of complement components in liver and the expression of liver 
genes associated with complement in animals with alcohol-induced liver injury were 
examined. It was demonstrated that chronic alcohol exposure leads to hepatic 
deposition of the complement components C1, C3, C8 and C9 in the livers of rats. 
Liver gene expression analysis showed that ethanol up-regulated the expression of 
transcripts for complement factors B, C1qA, C2, C3 and clusterin. In contrast, ethanol 
down-regulated the expression of the complement regulators factor H, C4bp and 
factor D and the terminal complement components C6, C8α and C9.      
 
Secondly, the role of the terminal complement pathway in the development of ALD 
was evaluated by using rats genetically deficient in the complement component C6 
(C6-/-). It was found that chronic ethanol feeding induced more liver pathology 
(steatosis and inflammatory changes) in C6-/- rats than in wild type rats. The hepatic 
triacylglyceride content and plasma alanine aminotransferase activity increased in 
C6-/- rats, supporting the histopathological findings and elevation of the plasma pro-
/anti-inflammatory TNF-α/IL-10 ratio was also more marked in C6-/- rats.  
 
Third, the role of the alternative pathway in the development of alcoholic liver 
steatosis was characterized by using C3-/- mice. In C3-/- mice ethanol feeding tended 
to reduce steatosis and had no further effect on liver triacylglyceride, liver/body 
weight ratio nor on liver malondialdehyde level and serum alanine aminotransferase 
activity. In C3-/- mice alcohol-induced liver steatosis was reduced also after an acute 
alcohol challenge. In both wild type and C3-/- mice ethanol markedly reduced serum 
cholesterol and ApoA-I levels, phospholipid transfer protein activity and hepatic 
mRNA levels of fatty acid binding proteins and fatty acid β-oxidation enzymes. In 
contrast, exclusively in C3-/- mice, ethanol treatment increased serum and liver 
adiponectin levels but down-regulated the expression of transcripts of lipogenic 
enzymes, adiponectin receptor 2 and adipose differentiation-related protein and up-
regulated phospholipase D1.  
 
In conclusion, this study has demonstrated that the complement system is involved in 
the development of alcohol-induced liver injury. Chronic alcohol exposure causes 
local complement activation and induction of mRNA expression of classical and 
alternative pathway components in the liver. In contrast expression of the terminal 
pathway components and soluble regulators were decreased. A deficient terminal 
complement pathway predisposes to alcoholic liver damage and promotes a pro-
inflammatory cytokine response. Complement component C3 contributes to the 
development of alcohol-induced fatty liver and its consequences by affecting 
regulatory and specific transcription factors of lipid homeostasis. 
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IV   REVIEW OF THE LITERATURE 
1.   ALCOHOL-INDUCED LIVER DISEASE (ALD) 
1.1.   Main features of ALD 
 
Although alcoholic liver disease (ALD) is recognized as a worldwide major health 
problem, the pathogenetic mechanisms are still poorly understood. ALD includes 
fatty liver (steatosis), hepatitis, fibrosis and liver cirrhosis, which develops in 10 - 20% 
of alcoholics. Recent experimental animal models of ALD have also shown a wide 
array of alcohol-induced hepatic changes including fatty liver, hepatocellular 
necrosis, infiltration by inflammatory cells, hepatic venular sclerosis, and proliferation 
of the smooth endoplasmic reticulum (MacSween and Burt 1986; Nanji et al. 1989; 
Nagy 2003, Nagy 2004; Deng 2005; Tsukamoto 2005). Fatty liver (steatosis) is the 
earliest stage of liver injury and the most common histological finding in ALD. It 
occurs in response to acute or chronic alcohol intake as a result of depletion of β-
oxidation of fatty acids, increase in TG synthesis and mobilization of extrahepatic free 
FA (Lieber 2004). Accumulation of neutral lipids in hepatocytes leads to micro- and 
macro-vesicular steatosis and ballooning cell degeneration (Tsukamoto 2005). Much 
evidence supports the notion that steatosis sensitizes the hepatocytes to more 
severe damage (Nanji et al. 1989). A common consequence is inflammation 
(steatohepatitis) associated with an increase in infiltrating granulocytes, monocytes 
and lymphocytes and hepatocyte death via necrosis and apoptosis (Bautista 2000; 
Diehl 2005). Alcohol-induced hepatic inflammation is considered a reversible 
condition, characterized by infiltration of polymorphonuclear leukocytes, hepatocyte 
degeneration and necrosis. It occurs as the most important precursor of liver 
cirrhosis. Hepatic fibrosis is a consequence of chronic ethanol consumption and is 
considered as the first irreversible stage of ALD (Worner and Lieber 1985; 
MacSween and Burt 1986). Hepatic fibrosis in ALD is characterized by the distortion 
of nomal hepatic architecture by scar tissue. The development of fibrosis and 
cirrhosis is a complex process that involves activation and transformation of both 
parenchymal cells and nonparenchymal hepatic stellate cells (HSCs) into 
myofibroblasts and an increased deposition of extracellular matrix in the liver 
(Friedman 2000). Oxygen-derived free radicals (O2–), inflammatory cytokines (TNF-α, 
IFN-γ, IL-6, IL-2), ethanol itself and its metabolite acetaldehyde are important 
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contributors to the activation of HSCs during liver injury (Lieber 1991; Niemelä et al. 
1995; Nieto 2006; Thirunavukkarasu et al. 2006).  
 
 
1.2.   Ethanol metabolism  
 
Ethanol is mainly oxidized to acetaldehyde in the liver by cytosolic alcohol 
dehydrogenase (ADH, EC 1.1.1.1). ADH is responsible for about 90% of ethanol 
oxidation. It is predominantly expressed in the liver and to a less extent in other 
tissues, including gastric mucosa, lungs and kidneys (Lieber 2000). Subsequent 
oxidation of acetaldehyde to acetate is catalyzed by aldehyde dehydrogenase (ALDH, 
EC 1.2.1.3). Genetic polymorphism of the ADH and ALDH genes and differential 
regulation at the transcriptional level contribute somewhat to ethanol elimination rate 
and to susceptibility to alcohol dependence and liver damage in humans (Lieber 
2000; Harada et al. 2001). The microsomal ethanol oxidizing system (MEOS, 
cytochrome P4502E1 (CYP2E1)) which is induced in chronic alcoholics, represents a 
minor pathway for ethanol elimination. The CYP2E1 pathway of ethanol oxidation 
generates reactive oxygen species that could contribute to ethanol-induced liver 
injury (Lieber 2000). Reduction of NAD during ethanol and acetaldehyde oxidation 
causes significant changes in cellular redox potential, provides more substrate for FA 
synthesis and diminishes mitochondrial β-oxidation. 
 
 
1.3.   Mechanisms and factors involved in ethanol-induced hepatic steatosis 
 
At the initial stage of alcohol consumption a shift in the NAD/NADH redox state of the 
hepatocytes results in accumulation of free FA. During ethanol oxidation the 
enhanced generation of NADH disrupts mitochondrial β-oxidation thereby diminishing 
the rate of lipid oxidation. This is one of the mechanisms of TG accumulation in the 
liver during chronic ethanol exposure. Specific transcription factors and genes are 
also involved in the regulation of lipid homeostasis during ALD development (Eaton 
et al. 1997; Koteish and Diehl 2001; Deaciuc et al. 2004 You and Crabb 2004 (a,b)).   
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SREBP-1 upregulation and increased expression of lipogenic enzymes by 
ethanol 
 
In a number of recent animal models chronic ethanol exposure has been found to 
increase expression of genes regulating FA synthesis, suppression of genes for FA 
oxidation and transport from the liver have been described. Specific transcription 
factors including sterol regulatory element binding protein (SREBP) and peroxisomal 
proliferating factor α (PPAR-α) regulate the expression of many of the genes involved 
in FA synthesis and oxidation (Smith 2002). Sterol response element binding proteins 
are a family of membrane-bound transcription factors that includes three isoforms: 
SREBP-1a, 1c and 2. SREBP-1a and 1c regulate genes involved in hepatic TG 
synthesis (acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1, 
malic enzyme, and ATP citrate lyase). SREBP-2 participates in the regulation of 
genes required for cholesterol synthesis (HMG-CoA synthase, HMG-CoA reductase) 
(Horton and Shimomura 1999; Horton et al. 2002). Overexpression of liver SREBP-
1a or SREBP-1c results in liver steatosis with dramatic increases in hepatic TG 
content. High expression of SREBP-1 was found in animals with experimental 
diabetes (ob/ob mouse), transgenic mice overexpressing SREBP-1c or SREBP-1a in 
adipose tissue, in ICAM-1−/−, a transgenic mouse fed high-fat diet (Shimomura et al. 
1999; Gregoire et al. 2002; Horton et al. 2003). Chronic ethanol intake induced an 
increased expression of SREBP-1 mRNA and protein in mouse liver (Ji and 
Kaplowitz 2003). An involvement of insulin-dependent mechanism in chronic ethanol-
induced SREBP-1 activation has been proposed (Horton et al. 2002). It was 
hypothesized that hyperhomocysteine-induced endoplasmic reticulum stress during 
intragastric ethanol exposure may be also related to induction of SREBP-1 mRNA (Ji 
and Kaplowitz 2003). ERK1/2-dependent phosphorylation by ethanol can enhance 
the transcriptional activity of SREBP-1 and SREBP-2 (Chen et al. 1998; Lee et al. 
2002). The mechanism of ethanol-induction of SREBP-1 may be also due to 
inhibition of the AMP-activated protein kinase (AMPK) catalyzed the phosphorylation 
of target enzymes, some of which are important rate-limiting enzymes in hepatic lipid 
metabolism. By inhibiting the activity of AMPK, ethanol relieves suppression of 
SREBP-1, causing its activation and increasing its levels in the nucleus (Donohue 
2007). 
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Down-regulation of the PPAR-α transcription factor and decline in FA oxidation 
by ethanol 
 
The peroxisome proliferator-activated receptor (PPAR) family of transcription factors 
belongs to the nuclear hormone receptor superfamily, which regulates the expression 
of genes involved in FA oxidation in mitochondria, peroxisomes and microsomes and 
possesses peroxisome proliferator response elements in their promoter regions (Lee 
et al. 1995; Reddy 2001). Such genes encode FA transporters (carnitine palmitoyl 
transferase, apolipoprotein B, the microsomal TG transfer protein, FA binding protein, 
and acyl-CoA dehydrogenase). In wild-type animals fasting increases the expression 
of PPAR-α-dependent genes regulating FA oxidation and PPAR-α-null mice develop 
a severe hepatic steatosis (Li et al. 2000). Chronic ethanol decreases PPAR-α 
mRNA expression in rats and decreases the PPAR-α DNA binding activity and 
transcriptional activation of PPAR-α-dependent genes in hepatoma cells or primary 
rat hepatocytes as reflected by a reduced binding by the RXR-PPAR-α complex to a 
PPAR-α-specific promoter sequence (Wan et al. 1995; Galli et al. 2001). This effect 
of ethanol is enhanced by using cyanamide, an ALDH inhibitor, and is abolished by 
the ADH inhibitor, 4-methylpyrazole. Decreased PPAR-α binding was associated with 
decreased expression of PPAR-α-dependent genes (medium chain acyl-CoA 
dehydrogenase) (Fischer et al. 2003). PPAR-α agonist (WY14, 643) restored PPAR-
α DNA binding activity and prevented the development of chronic ethanol-induced 
steatosis in mice (Fischer et al. 2003). Induction of PPAR-α by agonist in these 
animals blocked fatty liver development by accelerating FA oxidation.  
 
The role of adiponectin in alcohol-induced liver steatosis 
 
In addition to transcriptional factors, the regulatory factor adiponectin is involved in 
regulation of lipid metabolism. Adiponectin is a tissue-derived (mainly adipocyte-
derived) serum molecule (also called ACRP30 and GBP28), which is characterized 
by anti-inflammatory, antidiabetic and antiatherogenic properties. Adiponectin shares 
sequence homology with a family of proteins that show a characteristic N-terminal 
collagen-like region, a C-terminal, complement factor C1q-like globular domain and a 
TNF-α-like three-dimensional structure (Shapiro and Scherer 1998). Insulin 
resistance, obesity, type 2 diabetes mellitus and coronary artery disease are 
associated with decreased circulating adiponectin levels (Guo et al. 2007). 
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Adiponectin decreases hepatic TG deposition by reducing free FA plasma level and 
their hepatic influx (Bajaj et al. 2004; Lopez-Bermejo et al. 2004; Matsuzawa et al. 
2004). Adiponectin has an anti-inflammatory and antifibrotic effect in experimental 
murine models of liver damage, in non-alcohol fatty liver disease (NAFLD) and 
alcoholic fatty liver and in LPS-induced liver injury (Kamada et al. 2003; Xu et al. 
2003; Masaki et al. 2004). Chronic ethanol administration causes a significant 
reduction in circulating adiponectin, which is associated with ethanol-elicited 
reduction in FA oxidation. The condition can be restored by treatment with 
recombinant adiponectin (Xu et al. 2003). Moreover, such treatment decreases the 
levels of TNF-α, because adiponectin and TNF-α are known to regulate each other’s 
production. Adiponectin and TNF-α seem to have opposite effects on lipid 
metabolism and inflammation. Adiponectin antagonises both production and activity 
of TNF-α and TNF-α has been shown to inhibit adiponectin production (Diehl 2005). 
An imbalance in the production of adiponectin and TNF-α promotes damage in many 
tissues, including the liver (Hui et al. 2004). Accumulating evidence now suggests 
that hepato-protective activity of adiponectin is due, at least in part, to a direct anti-
inflammatory effect of adiponectin on Kupffer cells (Park et al. 2006).  
 
ADRP in liver steatosis 
Adipose differentiation-related protein (ADRP; also known as ADFP or adipophilin) is 
actively involved in hepatic lipid metabolism. ADRP is abundantly expressed in a 
variety of cells, including hepatocytes, macrophages, breast epithelium, and kidneys, 
in which ADRP coats lipid droplets (LD) (Brasaemle et al. 1997; Heid et al. 1998). 
ADRP shares sequence homology with other LD proteins including perilipin, Tip47 
and S3-12. ADRP activates long-chain FA uptake and TG formation, while 
suppression of ADRP decreases lipid accumulation in hepatocytes (Gao and Serrero 
1999; Imamura et al. 2002; Larigauderie et al. 2004; Schadinger et al. 2005). ADRP 
has been shown to increase in fatty liver in humans and rodents (Dalen et al. 2006; 
Motomura et al. 2006). It has been demonstrated that ADRP antisense 
oligonucleotide (ASO) treatment specifically decreases ADRP mRNA and protein 
levels in the livers of Lepob/ob mice and diet-induced obese mice. This resulted in 
suppression of lipogenic genes, reduction in TG secretion, reversal of hepatic 
steatosis and hypertriglyceridemia, and enhancement of insulin sensitivity (Imai et al. 
2007). Increased expression of ADRP was associated with FA accumulation in 
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hepatocytes in patients with nonalcoholic fatty liver disease with abnormal liver 
dysfunction (Kohjima et al. 2007). ADRP deficiency in mice caused reduction in 
hepatic TG and resistance to diet-induced fatty liver (Chang et al. 2006).  
 
 
1.4.   Role of Kupffer cells in ethanol-induced liver injury 
 
The innate immune system plays a significant role in the first line of defense against 
invading pathogens. Macrophages and neutrophils (phagocytic cells) participate in 
the response against invading pathogens. Experimental data suggest that Kupffer 
cells, the liver resident macrophages, play a key role in the pathogenesis of alcohol-
induced liver injury. For instance, Kupffer cell depletion by gadolinium chloride 
increases fatty infiltration, inflammation and necrosis as well as serum levels of AST 
and ALT and free radicals after chronic ethanol treatment (Wheeler et al. 2001; Hines 
and Wheeler 2004).  
 
1.4.1.   Role of endotoxin in Kupffer cell activation 
 
Endotoxin (lipopolysaccharide; LPS) has been shown to activate Kupffer cells after 
ethanol consumption (Nagy 2003; You and Crabb 2004 (a,b)). LPS is a component of 
the outer membrane of intestinal gram-negative bacteria (Han 2002; Thakur et al. 
2007). Gut-derived LPS in the portal blood may promote hepatocellular injury 
(Schafer et al. 2002). Moreover, sterilization of the gut with nonabsorbable antibiotics, 
which kill gram-negative bacteria, blocks alcohol-induced liver injury (Adachi et al. 
1995). Alcohol-induced increased gut permeability to endotoxin is considered to be 
one of the initial mechanisms by which ethanol increases Kupffer cell activation and 
subsequent cytokine production. Proinflammatory cytokines and chemokines 
released by Kupffer cells in response to LPS stimulation exert a range of autocrine 
and paracrine effects that initiate defense responses and promote infiltration of 
inflammatory cells and induced oxidative responses in the liver (Nanji et al. 1993; 
Thurman 1998; Enomoto et al. 2000; Bode and Bode 2003). Ethanol is known to alter 
cytokine levels and mRNA expression in a variety of tissues including blood, lung, 
liver, and brain. Proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, are 
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released from Kupffer cells or infiltrating neutrophils and macrophages and elicit 
defensive responses in parenchymal cells, including activation of apoptosis often 
seen in alcoholics and animals treated with ethanol. A significant role for TNF-α in 
ethanol-induced hepatotoxicity has been indicated both by clinical observations and 
in animal studies (McClain et al. 1999; Tilg and Diehl 2000). In support, treatment 
with neutralizing antibodies to TNF-α and depletion of Kupffer cells has been found to 
suppress ethanol-induced liver injury (Adachi et al. 1994; Iimuro et al. 1997).  
 
1.4.2.   CD14 endotoxin receptor  
 
It is well known that LPS bound to LPS-binding protein (LBP) interacts with the CD14 
endotoxin receptor, a glycosyl-phosphatidylinositol-anchored membrane protein, 
found on mononuclear cells, including Kupffer cells. To initiate an intracellular 
responce CD14 requires an association with Toll-like receptors (TLR) because CD14 
does not have a transmembrane-spanning domain. CD14 and TLR appear to be 
involved in the development of alcohol-induced liver injury. Experimental chronic 
ethanol exposure has been found to upregulate the expression of CD14 mRNA and 
protein, and CD14- and LBP-deficient mouse strains are resistant to alcohol-induced 
liver injury (Su et al. 1998; Lukkari et al. 1999; Uesugi et al. 2002). An association 
between human ALD and polymorphisms in the promoter of the CD14 gene has been 
described (Järveläinen et al. 2001). Chronic ethanol intake also sensitizes Kupffer 
cells to LPS-mediated activation by increasing the ability of LPS to stimulate 
members of the mitogen-activated protein kinase family, ERK1/2 and p38 
(Järveläinen et al. 1997; Kishore et al. 2001; Cao et al. 2002; Kishore et al. 2002; 
Koteish et al. 2002).  
 
1.4.3.   Transcriptional factors 
 
It is widely accepted that also reactive oxygen species (ROS) play a significant role in 
the development of ALD probably in Kupffer cell activation. ROS participate in the 
activation of NF-κB and may have an indirect effect on signaling pathways and on the 
ubiquitin-proteosomal pathway for protein degradation (Hoek et al. 1992; Hoek and 
Pastorino 2002). Inhibition of NF-κB activity in the liver via transduction with the IκB 
super-repressor prevents alcohol-induced liver injury. This demonstrates the 
functional significance of NF-κB activation in the pathogenesis of ALD (Uesugi et al. 
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2001). Activation of activator protein 1 (AP-1) by ethanol can also be important in 
mediating the inflammatory phase of ethanol-induced liver injury. AP-1 regulates the 
transcription of genes involved in inflammation and fibrosis, including TNF-α, CD14, 
matrix metalloproteinases and collagen type I (Armendariz-Borunda et al. 1994; Tsai 
et al. 2000; Wheeler and Thurman 2003).  
 
1.4.4.   Cytokines 
 
TNF-α is one of the principal mediators of the inflammatory response in mammals. It 
provides transducing differential signals that regulate cellular activation and 
proliferation, cytotoxicity and apoptosis. On hepatocytes TNF-α acts through two 
types of plasma membrane receptors: p55 [type 1 tumor necrosis factor receptor 
(TNFR1)] and p75 [type 2 tumor necrosis factor receptor (TNFR2)] (Yin et al. 1999). 
Binding of TNF-α to TNFR1 leads to activation of the apoptotic machinery or to 
cytoprotective responses in hepatocytes.  
 
Increased serum TNF-α levels in patients with ALD have been found to correlate with 
mortality, supporting the idea that TNF-α may be important in ALD. Moreover, mice 
deficient in TNFR1 exhibited essentially no pathological changes in liver and plasma 
after chronic ethanol treatment. Kupffer cells also produce large amounts of 
potentially damaging free radicals including superoxide via phagocytic NADPH 
oxidase system. It has been shown that mice deficient in p47phox, a regulatory subunit 
of the oxidase, after 4 wk of enteral ethanol feeding, had significantly reduced liver 
injury and blunted cytokine production indicating a link between oxidant production 
and cytokine generation in this model of ALD (Kono et al. 2000). Suppression of 
inflammatory gene expression, inhibition of neutrophil recruitment, removal of 
inflammatory cells by apoptosis and phagocytosis and induction of anti-inflammatory 
mediators are involved in the resolution of an inflammatory response in alcohol liver 
injury (Gregory and Wing 2002). The balance between both pro- and anti-
inflammatory cytokines seems to be important in order to assess the nature of 
inflammatory response (Latvala et al. 2005). IL-10, glucocorticoids, cAMP, and 
prostaglandins are important anti-inflammatory mediators. Chronic ethanol 
consumption causes an enhanced expression of the most potent anti-inflammatory 
cytokine IL-10 in rodents (Koteish et al. 2002; Lawrence et al. 2002). IL-10 is known 
as a cytokine synthesis inhibiting factor and represents one of the most important 
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immune-regulating cytokines. IL-10 has multiple biological effects on different cell 
types. It is produced by macrophages, T cells, B cells, mast cells, keratinocytes, and 
some tumor cell lines (Moore et al. 1993; Moore et al. 2001). The effect of IL-10 on 
immune responses is mostly inhibitory on T cells. It suppresses macrophage 
production of cytokines and chemokines (McInnes et al. 2001; Denys et al. 2002). It 
has been shown, that IL-10 may protect against hepatotoxicity in several models of 
experimental liver injury including acetaminophen-, concanavalin A- and LPS-
induced liver injury (Emoto et al. 2003; Bourdi et al. 2007; Erhardt et al. 2007).  
 
 
2.   THE COMPLEMENT SYSTEM  
Complement is a central part of the innate immune system. It plays an important role 
in defense against invading pathogens and in the clearance of cellular debris. 
Complement has multiple functions including opsonization of pathogens and debris 
by C3b, regulation of inflammation via anaphylatoxic fragments C5a and C3a and in 
providing a link between innate and adaptive immunity through C3 receptors on B 
cells and antigen-presenting cells. The complement system consists of about 40 
different proteins found in blood, other body fluids as well as cells and tissues.  
C1q, C4b, C3b, and iC3b are ligands for complement receptor 1 (CR1) and 
complement receptor 3 (CR3). Phagocytosis is mediated by receptors CR1 and CR3, 
which are localized e.g. on neutrophils and antigen presenting cells such as 
macrophages.  
Complement-mediated inflammation is generated primarily by the activation products 
C3a and C5a. They increase vascular permeability and contraction of smooth muscle 
cells. C3a and C5a act also as chemotactic homing signals for leukocytes to sites of 
inflammation. By binding to specific receptors (C5aR and C3aR), C5a and to a lesser 
extent also C3a, mediate anaphylaxis e.g. by releasing histamine from mast cells. 
Membrane attack complex of complement (MAC) itself can also activate cells via 
Ca2+ influx to release leukotrienes, prostaglandins and other inflammatory mediators 
to induce further inflammatory changes in tissues.  
Complement also participates in the clearance of necrotic and apoptotic cells from 
damaged or regenerating tissues. This occurs via opsonization of immune complexes 
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and cellular debris by C3b and C4b. C1q also recognizes apoptotic cells or blebs 
directly resulting in opsonization and phagocytosis. A deficiency or failure in this 
system leads to systemic lupus erythematosus with characteristic symptoms. 
Complement system is also involved in certain pathological conditions such as 
different forms of nephropathy and ischemia/reperfusion injury. 
 
 
2.1.   Complement activation pathways 
 
Complement activation occurs via three different pathways: the classical pathway 
(CP), the alternative pathway (AP) and the lectin pathway (LP) (Fig 1). In the final 
common step a protein complex, the MAC on a complement-activating surface is 
formed. 
 
 
2.2.   Classical pathway (CP) 
 
The CP is activated when its recognition molecule C1q binds to immunoglobulins 
(IgG, IgM), certain acute phase protein (CRP, SAP, PTX3), charged molecules, 
apoptotic or necrotic cell debris (Mold et al. 1999; Walport 2001 (a,b)). Binding to 
surface induces a conformational change in the C1q and results in the activation of 
the associated molecules C1r and C1s. C4b2a complex is formed by the C1s-
induced activation of C4 and C2, and further activates the central complement 
component C3.  
 
 
2.3.   Alternative pathway (AP) 
 
Activation of the antibody-independent AP is due to C3(H2O), which is continuously 
formed by spontaneous hydrolysis of an internal thioester in C3 (Pangburn and 
Müller-Eberhard 1986; Thurman and Holers 2006; Zipfel et al. 2007). Activated C3 
binds factor B, whereafter factor B is cleaved and activated by factor D and 
C3(H20)Bb is formed. This complex is stabilized by properdin and can subsequently 
activate further C3 molecules to C3b. C3b can bind factor B and the subsequent 
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activation of factor B leads to the formation of a C3bBb convertase and cleavage of 
further C3. Factor H and I control the activation of the alternative pathway by 
degrading C3b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alternative pathway Classical pathway Lectin pathway 
C3b/C3(H2O)  
C3bB
Microbes, fungi, viruses, 
LPS, “non-self” particles 
Ag + IgG/IgM, apoptotic 
cells, CRP, SAP, PTX3 
Man/GlcNAc 
Factor D 
C3bBb  
C1q 
C1qrs 
C4b2a 
C4   C2
C5 
C5b 
TCC/MAC 
Factor B 
C6, C7, C8, C9n 
 MASP-1 
MASP-2 C3 
C3b 
MBL 
 
 
Figure 1. The complement activation cascades. The dashed lines indicate enzymatic 
activities, brickets – active enzyme or enzyme complex. CRP – C reactive protein, LPS – 
lipopolysaccharide, SAP - serum amyloid P component, PTX3 – pentraxin 3, Man – 
mannose, GlcNAc – N-acetyl glucosamine, MBL - mannan-binding lectin, MASP - mannan-
binding lectin associated serine protease, TCC/MAC - terminal complement 
complex/membrane attack complex of complement. 
 
 
2.4.   Lectin pathway (LP) 
 
Initiation of the LP occurs when plasma mannan-binding lectin (MBL) binds directly to 
mannose or N-acetyl glucosamine residues present abundantly on target cells e.g. 
yeast. MBL has a structure similar to that of C1q and ficolins (L-ficolin and H-ficolin). 
After binding it activates MBL-associated serine proteases (MASPs-1 to -3) (Turner 
1996; Schwaeble et al. 2002). Only MASP-2 has a role in complement activation, 
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corresponding to that of C1s in the CP (Thiel et al. 1997; Rossi et al. 2001). MASP-2 
cleaves C4 to produce the C4a and C4b fragments and C2 to generate C2b and 
C2a. C4b and C2a together form the C3 convertase (C4b2a), the enzyme that 
catalyses the next step in the reaction pathway (Kerr 1980). 
 
 
2.5.   Terminal pathway (TP) 
Activation of complement leads to the TP, which is the same for all three initiating 
pathways.  C5 is cleaved by either the classical or the alternative C5 convertase and 
subsequent binding of C6, C7, C8, and C9 results in the formation of the terminal 
complement complex (TCC) The membrane associated form is called the membrane 
attack complex (MAC). C5b binds C6 to form the stable bimolecular complex C5b6. If 
C7 availability is limited, the stable bimolecular C5b6 complex remains in solution. In 
the presence of C7 fluid phase C5b-7 is formed. This form has an ability to attach to 
target membranes (Thompson and Lachmann 1970). Membrane-bound and fluid-
phase C5b-7 are capable of binding C8. C5b-8 initiates polymerization of C9 by 
binding C9 via C8. Formation of the C5b-9 complex results in water permeable 
hydrophilic pores which are inserted in the phospholipid bilayer of the membranes. 
Finally, MAC causes rupture of the cell membranes of a susceptible target cell. It has 
been suggested that the complement system plays a role as a physiological waste-
disposal mechanism, particularly in the clearance of dying cells and immune 
complexes and that complement deficiency impairs normal mechanisms of waste 
disposal and, consequently, this material can be a source of autoantigens (Botto and 
Walport 1994). On host nucleated cells, complement activation is often sublytic, 
which offers some protection to the cell, when they activate their defense systems 
(Morgan 1989 (a,b)).  
 
2.5.1.   Complement–mediated lysis of cells 
MAC formation is critical for complement-mediated lysis of target cells. Insertion of 
C9 through the cell lipid bilayer membranes and polymerization results in the 
formation of water permeable hydrophilic pores and subsequent rupture of the cell 
membranes. The efficiency of the lysis depends on the number of MACs on the cell 
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membrane (Cole and Morgan 2003). Erythrocytes are much more sensitive to the 
lytic effects of complement compared to nucleated cells. The latter are better 
protected because of a variety mechanisms including ion pumps, mechanisms for 
removal of the MAC and a more abundant presence of membrane-bound 
complement regulators (Morgan 1989 (a)). MACs can be removed by shedding of 
membrane vesicles (ectocytosis) or by internalization and degradation (Carney et al. 
1985; Morgan et al. 1987; Scolding et al. 1989). 
 
2.5.2.   Non-lytic effects of the complement 
MAC also affects the inflammatory response by activating neutrophils and 
macrophages to produce and release inflammatory mediators (prostaglandins, 
thromboxanes, leukotrienes and reactive oxygen species) (Hansch et al. 1984). 
Several signal transduction pathways are initiated by Ca2+ intake and the activation of 
receptor tyrosine kinases, G-proteins, MAP kinase,  NF-kB and c-Jun N-terminal 
kinase pathways (Cybulsky et al. 1990; Cybulsky et al. 1999; Rus et al. 2001; Takano 
et al. 2001; Peng et al. 2002). A role for non-lytic activating effects of the MAC has 
been described in glomerulonephritis, dilated cardiomyopathy vascular smooth 
muscle proliferation and remodelling in atherosclerosis (Niculescu and Russ 1999). 
MAC has also been implicated as a stimulus to cell proliferation in models of 
mesangioproliferative glomerulonephritis, diabetes (retinopathy and nephropathy), 
atherosclerosis and production of platelet-derived (PDGF) and basic fibroblast growth 
factors (bFGF) (Benzaquen et al. 1994; Brandt et al. 1996; Niculescu et al. 1999). 
Sublytic MAC can directly stimulate proliferation of different kind of cells like aortic 
smooth muscle cells and Schwann cells (Niculescu et al. 1999; Dashiell et al. 2000).  
 
2.5.3.   Complement and apoptosis  
Complement plays significant roles in regulating apoptosis, which is important in 
development and homeostasis, embryogenesis and tissue remodeling (Nauta et al. 
2003). Several different products of complement including anaphylatoxins participate 
in this process. C5a inhibits spontaneous apoptosis of neutrophils and protects 
neurons from glutamate neurotoxicity, probably via inhibition of caspase 3 activity 
 20
(Lee et al. 1993; Pitt et al. 2000; Mukherjee and Pasinetti 2001). C3a has also been 
shown to protect neurons from apoptosis induced by N-methyl-D-aspartate (van 
Beek et al. 2001). Non-lytic MAC also modulates apoptosis by promoting the survival 
of oligodendrocytes, increasing Bcl-2 transcription and suppressing the activation of 
caspase 3. It also up-regulates anti-apoptotic genes and down-regulates pro-
apoptotic genes in the brain as shown in the rodent multiple sclerosis model (Rus et 
al. 2006). Complement has been implicated in cell apoptosis in 
ischaemia/reperfusion injury, myocardial infarction and stroke models (D'Ambrosio et 
al. 2001; Monsinjon et al. 2001). Blocking the generation of MAC and C5a by anti-C5 
antibodies attenuated both lysis and apoptosis of myocardial cells (Daemen et al. 
1999). Complement participates in the clearance of apoptotic cells by helping 
professional phagocytes and to prevent an inflammatory response (Fadok et al. 
1998; Savill and Fadok 2000). C1q and mannan-binding lectin, can bind blebs that 
initiate activation of the CP and LP and deposition of other complement fragments 
(Korb and Ahearn 1997). C1q binds specific receptors on the phagocyte surface, 
including CD91 and calreticulin to recruit phagocytes and initiate phagocytosis. C3 
fragments deposited on the apoptotic cells bind to receptors CR1, CR3 and CR4 on 
the phagocytes to mediate recognition and clearance (Takizawa et al. 1996; Ogden 
et al. 2001). Defects in the removal of apoptotic cells can induce autoimmune 
pathology, like SLE, supporting the so called “waste disposal” hypothesis (Walport 
2001 (b)). Persisting apoptotic cells or their fragments may generate an autoimmune 
response because cytoplasmic and nuclear antigens become exposed at the cell 
surface or outside the lysed cell and may provide signals to T cells and antigen-
presenting cells, which stimulate autoreactive B cells to differentiate into plasma cells 
and start producing autoantibodies (Mohan et al. 1993; Savill and Fadok 2000; 
Fishelson et al. 2001). 
 
 
2.6.   Complement regulation 
 
By regulating the complement system host cells can inhibit activation of complement 
occurring in vivo. There are 10 plasma and membrane-bound proteins that regulate 
complement activation and prevent against complement attack host cells (Table 1, 
Fig 2). 
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2.6.1.   Soluble plasma complement regulators 
 
Soluble plasma complement regulators prevent excessive complement activation in 
the fluid phase. 
 
C1 inhibitor (C1INH) 
 
C1INH is an inhibitor of the CP (Cicardi et al. 2005; Wagenaar-Bos and Hack 2006). 
It inhibits C1r and C1s serine esterases by irreversible covalent binding. A deficiency 
in C1INH causes hereditary angioedema, a disease characterized by attacks of 
edema and pain (Frank 2005). In addition C1INH also inhibits MASP1 and MASP2 to 
prevent LP activation.   
 
Table 1. Complement regulators 
Protein Function 
  
Soluble regulators  
  
C1 inhibitor (C1INH) Inhibitor of C1r and C1s serine esterases and 
MASP1 and MASP2 
C4b-binding protein (C4bp) Accelerates decay of C4b2a, cofactor for cleavage 
of C4b by FI 
Factor I Cleaves C3b and C4b  
 
Factor H Decay acceleration activity for the C3/C5 convertase 
of AP, cofactor for FI 
Vitronectin Inhibits C5b-7 complex insertion into membrane 
 
Clusterin  Inhibits C5b-7 complex insertion into membrane 
 
  
Membrane regulators  
  
Membrane cofactor protein (MCP; 
CD46)  
Cofactor for factor I-mediated cleavage of C3b and 
C4b 
Decay accelerating factor (DAF; 
CD55)  
Decay acceleration activity for the C3/C5 
convertases   
Protectin (CD59)  Inhibition of MAC formation 
 
Complement receptor 1 (CR1)  Decay acceleration activity for the C3/C5 
convertases, cofactor for factor I, immune complex 
processing and clearance 
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C4b-binding protein (C4bp) 
 
C4bp accelerates the decay of the CP C3-convertase C4b2a by promoting 
dissociation of C2a. It can also function as a cofactor in the cleavage of C4b by FI 
(Blom et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C3b/C3(H2O)  
C3bB 
Factor D 
C3bBb  
C1q 
C1qrs 
C4b2a 
C4  C2 
C5 
C5b 
TCC/MAC 
Factor B
C6, C7, C8, 
 MASP-1 
MASP-2 C3 
C3b 
MBL 
CD59
Clusterin 
Vitronectin 
CR1  
DAF 
Factor H 
C1 INH 
 Factor I 
C4BP 
Factor H
MCP 
CR1
Factor I 
MCP 
CR1 
 
 
Figure 2. Regulation of complement activation. Soluble complement regulators are in the 
ovals, membrane-bound complement regulators are in the brickets. Thick arrows indicate an 
inhibitory function. 
 
Factor H  
 
Factor H is an essential regulatory protein that plays a critical role in the homeostasis 
of the complement system in plasma and in the protection of bystander host cells and 
tissues from damage by complement activation (Atkinson and Goodship 2007). 
Factor H is a glycoprotein (155 kDa) with a single polypeptide chain. The secreted 
form of the protein is composed of 20 repetitive units of 60 amino acids called short 
consensus repeats (SCR) (Nilsson and Müeller-Eberhard 1965; Ripoche et al. 1988). 
Factor H accelerates the decay of the alternative pathway C3-convertase (C3bBb) by 
binding C3b and acting as a cofactor for the factor I-mediated proteolytic inactivation 
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of C3b (Weiler et al. 1976; Whaley and Ruddy 1976; Pangburn et al. 1977). In the 
presence of factor H, factor I cleaves the α′-chain of C3b at two nearby sites 
generating two fragments of 68 and 43 kDa, respectively. The inactivated C3b 
surface-bound molecule, named iC3b, remains covalently linked to the activating 
surface. 
 
Factor I 
 
Factor I is a serine esterase that prevents the formation of the AP and CP C3 and C5 
convertases by cleaving C3b and C4b to iC3b, C3c, C3dg and C4c, C4d, 
respectively (Sim 1993; Sim and Laich 2000).  
 
Vitronectin and clusterin  
 
Vitronectin and clusterin interact with the terminal complexes (C5b-7, C5b-8 and 
C5b-9) of complement and inhibit their insertion into lipid membranes (McDonald and 
Nelsestuen 1997; Preissner and Seiffert 1998). 
 
 
2.6.2.   Membrane regulators of complement  
 
Complement regulatory proteins on cell membranes protect host tissues from injury, 
when complement is activated (Miwa and Song 2001). The regulatory membrane 
proteins anchored on cell surfaces are complement receptor 1 (CR1; CD35), decay-
accelerating factor (DAF; CD55), membrane cofactor protein (MCP; CD46), and 
CD59. With the exception CD59 they belong to a family of proteins (regulators of 
complement activation, RCA) encoded by a gene cluster on chromosome 1. There 
are differences in the composition of membrane complement regulatory proteins 
between man and mouse. DAF and CD59 genes are duplicated in the mouse (daf-1, 
daf-2, cd59a and cd59b) (Spicer et al. 1995; Song et al. 1996; Powell et al. 1997; 
Qian et al. 2000). Daf-2 and cd59b are expressed only in the mouse testis whereas 
daf-1 and cd59a are expressed broadly. In man MCP is expressed on all cells except 
erythrocytes whereas in the mouse MCP expression is restricted to the testis (Cole et 
al. 1985; Nickells and Atkinson 1990; Liszewski et al. 1991; Johnstone et al. 1993; 
Miwa et al. 1998). In the mouse Crry (complement-receptor 1-related gene/protein y) 
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possesses both MCP and DAF activities (Holers et al. 1992; Li et al. 1993; Paul et al. 
1989; Song 2004).  
 
Membrane cofactor protein (MCP; CD46)  
 
MCP is regulator of C3 activation by functioning as a membrane associated cofactor 
protein for factor I-mediated cleavage of C3b to inactive iC3b and of C4b to iC4b 
(Liszewski et al. 1991). MCP associates with the plasma membrane via its C-terminal 
transmembrane domain and an intracellular cytoplasmic tail. 
 
Decay accelerating factor (DAF; CD55)  
 
DAF inhibits the activation of C3 and C5 by preventing the formation of new and 
accelerating the decay of preformed C3 and C5 convertases (Lublin and Atkinson 
1989). DAF is anchored to cell membranes via a glycosylphosphatidylinositol anchor.  
 
Protectin (CD59)  
 
CD59 regulates TP on cell membranes by preventing formation of the final assembly 
of the membrane C5b-9 complex. It binds to C8 and C9 molecules and blocks their 
insertion into cell membranes (Meri et al. 1990). Protectin is anchored to cell 
membranes via glycosylphosphatidylinositol anchor.  
 
Complement receptor 1 (CR1)  
 
CR1 has both DAF and MCP activities and functions as a receptor for C3b and C4b. 
CR1 is a major immune adherence receptor and plays a role in immune complex 
processing and clearance (Ahearn and Fearon 1989). CR1 associates with the 
plasma membrane via its C-terminal transmembrane domain. 
 
2.7.   The role of C3 in pathology  
 
By participating in inflammatory reactions and elimination of invading foreign, 
apoptotic or injured cells, the complement system can play a significant role in the 
pathogenesis of different diseases. 
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2.7.1.   C3 and inflammation 
 
Complement activation leads to the generation of inflammation-inducing 
anaphylatoxins (complement activation products C3a, C4a and C5a). C3a 
participates in the process of liver regeneration and Kupffer cell activation (Puschel et 
al. 1993; Schieferdecker et al. 1997; Strey et al. 2003). C3 plays a central role in all 
three activation pathways participating in the formation of C3- and C5-convertases, 
production of opsonins for phagocytosis through generating C3b and iC3b, which are 
ligands for complement receptors CR1, CR3 and CR4 present on phagocytic cells 
(Lambris 1988). C3a and C5a binding to their receptors (C3aR and C5aR) leads to 
the degranulation of mast cells and basophils to release vasoactive mediators and 
cause an inflammatory reaction. C3 participates in the solubilization and clearance of 
immune complexes and in the clearance of apoptotic cells. iC3b bound to dead cells 
or cell debris is recognized by CR3 and CR4 receptors on the macrophage surface 
(Davies et al. 1994; Mevorach et al. 1998).  
 
 
2.7.2.   C3 deficiency  
 
In humans a primary (inherited) C3 deficiency is associated with recurrent bacterial 
infections, mainly caused by gram-positive bacteria, usually pneumococci. Clinical 
manifestation of C3 deficiency includes infections in the upper and lower respiratory 
tracts (pneumonia, sinusitis, tonsillitis, otitis or meningitis), renal impairment 
(membranoproliferative glomerulonephritis) or autoimmune diseases (Imai et al. 
1991; Homann et al. 1997). Acquired C3 deficiency is observed in patients with 
impairment in the regulatory proteins factor I or factor H. Amplification of C3 cleavage 
by an unregulated C3bBb C3-convertase results in S. pneumoniae and N. 
meningitidis infections or in diseases caused by excessive complement activation in 
blood vessels or kidneys (SLE, hemolytic uremic syndrome, membranoproliferative 
glomerulonephritis). 
  
In animals, like guinea-pigs, partial C3-deficiency induced decreased bactericidal 
activity and an abnormal antibody responses to T-cell-dependent antigens (Auerbach 
et al. 1990). C3-deficient dogs suffered from severe bacterial infections and major 
renal pathology (Ameratunga et al. 1998). The use of cobra venom factor (CVF) for 
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depleting complement proteins induced lower amounts of specific antibodies against 
sheep red blood cells, impaired production of specific antibodies against another T-
dependent antigen (phage φX174) and enhanced susceptibility to group B 
streptococcal infection and defective opsonization (Wessels et al. 1995). In pigs with 
factor H deficiency membranoproliferative glomerulonephritis type II was associated 
with excessive complement activation shown by low plasma C3, high plasma TCC 
and complement deposition in the renal glomeruli (Høgåsen et al. 1995). The use of 
C3-deficient mice (C3-/-) or inhibition of complement activation with the C3 convertase 
inhibitor Crry-Ig prevented anti-phospholipid syndrome, fetal loss and growth 
retardation (Thurman et al. 2005). 
 
 
2.7.3.   C3 and lipid metabolism  
 
Recent studies demonstrate a strong association between complement and lipid 
metabolism. Activation of the CP or AP leads to cleavage of the complement 
component C3 to the pro-inflammatory C3a fragment. C3a can be cleaved to 
C3adesArg by carboxypeptidase N or R (Campbell et al. 2001). C3adesArg has also been 
referred to as acylation-stimulating protein, ASP (Baldo et al. 1993). Both ASP and its 
precursor C3a have been suggested to be involved in the regulation of FA uptake to 
adipose tissue and body lipid homeostasis (Cianflone et al. 2003). Experimental data 
suggest that ASP stimulates TG synthesis in adipocytes and intracellular uptake of 
glucose by adipocytes. It increases the activity of diacylglycerol acyltransferase, 
stimulates reesterification of free FAs into TG in adipocytes and reduces endogenous 
FA production by inhibiting a hormone-sensitive lipase (Faraj et al. 2004). These 
results have been obtained from experiments with C3-/- mice, which cannot generate 
ASP and manifest various metabolic alterations in their lipid metabolism. C3-/- mice 
crossed with mice deficient in both apolipoprotein E and low-density lipoprotein 
receptor (ApoE-/- LDLR-/-) exhibited increased serum TG concentrations and a more 
proatherogenic lipoprotein profile with more LDL cholesterol and VLDL TG, than 
control mice (Persson et al. 2004). The C3-/- mice showed also a delayed 
postprandial TG clearance, an effect that is normalized by administration of ASP 
(Murray et al. 1999). In patients with nonalcoholic fatty liver disease (NAFLD) high 
plasma ASP and C3 levels were associated with liver steatosis (Yesilova et al. 2005).
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2.8.   The role of C6 in pathology 
 
Full activation of the complement leads to the assembly of the lytic MAC, which 
consists of the terminal components C5b, C6, C7, C8 and multiple C9 molecules. 
Loss of ability to protect cells can lead to “self-damage” when complement is 
activated, targets are opsonized, excessive inflammation-inducing anaphylatoxins 
(complement fragments C3a, C4a and C5a) are generated and the MAC forms on 
cell surfaces (Straatsburg et al. 2000). The TP has been implicated in a large number 
of diseases and plays a crucial role in various pathological conditions (Niculescu et 
al. 1999; Niculescu and Rus 1999; Walport 2001 (a, b); McGeer and McGeer 2002). 
Deficiencies of the TP predispose to meningococcal infections, indicating that its 
cytolytic properties are of particular importance in host defense against Neisseria 
(Lehner et al. 1992; Würzner et al. 1992).  
Complement component C6 plays an essential role in the formation of a stable C5b-9 
terminal complement complex (Esser 1994). A number of experimental disease 
models have been studied in the PVG/C6– rat characterized by deficiency in C6 and 
loss of the ability to mediate complement-dependent lysis. These animals have been 
shown to lack both antigenic and functional C6 due to a 31-bp deletion in exon 10 of 
the C6 gene (van Dixhoorn et al. 1997). It has been shown that in models of 
inflammatory glomerulonephritis PVG/C6– rats had less proteinuria and apoptosis 
compared with normal PVG/c rats and were also protected from thrombotic 
microangiopathic glomerulonephritis, hyperacute rejection of xenografts and 
experimental autoimmune encephalomyelitis (Brauer et al. 1993; Nangaku et al; 
1997; Sato et al. 1999; Tran et al. 2002). Studies have suggested that C6 may be 
important in atherosclerotic lesion progression. When C6-deficient rats were fed a 
cholesterol-rich diet for 14 week a protective effect of C6 deficiency on the 
development of diet-induced atherosclerosis was seen (Schmiedt et al. 1998). 
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3.   COMPLEMENT SYSTEM AND THE LIVER    
3.1. Biosynthesis of plasma complement components and complement 
receptor expression in the liver 
 
Most complement components are produced mainly in the liver (CP: C1r/s, C2, C4, 
C4bp; AP: C3, factor B; LP: MBL, MASP1-3; TP: C5, C6, C8, C9; and soluble 
regulators (factors I, H, C1 inhibitor)) (Morris et al. 1982; Morgan and Gasque 1997; 
Schwaeble et al. 2002). C1q is produced by epithelial cells, fibroblasts, monocytes 
and macrophages (Tenner and Volkin 1986). Factor D is mainly produced in 
adipocytes while properdin and C7 are synthesized by macrophages and monocytes 
(Choy et al. 1992; Maves and Weiler 1993; Wurzner et al. 1994). Membrane bound 
complement components – CD59, CD35, CD46, and CD55 are produced by nearly 
all cell types (Mead et al. 1999; Harris et al. 1999; Qin X et al. 2001). Hepatocyte 
nuclear factors (HNF1, HNF3 and HNF4) as well as proinflammatory cytokines (IL-6, 
IL-1, TNF-α, INF-γ) control transcription of the complement components (Garnier et 
al. 1996; Phillips et al. 1996; Pontoglio et al. 2001; Stapp et al. 2005). 
 
Several complement receptors are expressed in the liver. Acute phase response and 
glucose release can be detected in hepatocytes after LPS challenge or partial 
hepatectomy (Schieferdecker et al. 2001; Koleva et al. 2002). In Kupffer cells 
complement receptors CR1 (C3b-receptor, CD35), CR3 (iC3b- and β-glucan-receptor 
CD11/CD18) and CR4 (iC3b-receptor, CD11c/CD18) are expressed at high levels 
and participate in the clearance of C3-opsonized immune complexes from blood 
(Schieferdecker et al. 1997; Yan et al. 2000). Stimulation via C5aR leads to 
hepatocyte proliferation. C5aR can also be detected on Kupffer and stellate cells and 
plays an important role in the release of prostanoids, proinflammatory cytokine 
regulation and in the expression of fibronectin (Schieferdecker et al. 2001; Schlaf et 
al. 2004). Thus the liver produces the bulk of plasma complement components and 
expresses a variety of complement receptors, which are involved both in liver injury 
and repair. 
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3.2.   Complement system and liver diseases 
 
The role of the innate immune system in the development of liver diseases has been 
extensively studied (Bode et al. 2005; Hoek et al. 2006; Qin and Gao 2006). In 
addition to systemic effects on lipid metabolism, C3a and also the related 
anaphylatoxin C5a have recently been suggested to participate in the process of liver 
regeneration via activation of nuclear factors and cytokines (Strey et al. 2003). Both 
C3a and C5a mediate LPS-induced pathogenic insults by stimulating the production 
of prostanoids and pro-inflammatory cytokines by liver Kupffer cells (Puschel et al. 
1993; Schieferdecker et al. 1997). C3 or C5 deficiency resulted in diminished liver 
regeneration after partial hepatectomy. This could be restored by C3a and C5a 
reconstitution (Strey et al. 2003). Severely defective liver regeneration was found in 
C5- and C3- or C3a receptor-deficient mice after CCL4-induced liver damage, which 
could be restored by murine C5, C5a or C3a (Mastellos et al. 2001; Markiewski et al. 
2004). 
 
There is evidence for the role of complement system in the pathogenesis of liver 
fibrosis. The involvement of C5 and C5aR in liver fibrosis has been shown using A/J 
inbred mouse strain that carries a 2-bp deletion of the C5 gene. This strain is 
resistant to liver fibrosis and develops low level of fibrosis after CCL4 treatment 
(Hillebrandt et al. 2005). The significance of C5 in liver fibrosis is supported by the 
induction of fibrosis-susceptible phenotype by the introduction of C5 deficiency into 
the C5 sufficient strain, and by the attenuation of liver fibrosis after blockade of the 
C5 receptor (C5aR1). Stimulation of C5aR1, which is expressed on the stellate cells, 
by C5a upregulated fibronectin expression (Schlaf et al. 2004).  
 
In patients with HBsAg-positive hepatitis and in primary biliary cirrhosis increased 
C3d concentrations and changes in the serum concentrations of the complement 
components consistent with activation of the CP and AP have been found (Munoz et 
al. 1982). A decreased total hemolytic complement activity and low concentrations of 
C3, C4, C5, factor B, and of the regulatory proteins factors I and H were observed in 
the patients with liver disease due to alcohol or acetaminophen toxicity (Ellison et al. 
1990). This impairment in complement function could contribute to impaired 
antibacterial host defense of patients with chronic hepatic disease. 
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Complement has been shown to be an important factor in the pathogenesis of the 
ischemia/reperfusion (I/R) liver injury (Chan et al. 2003). Reperfusion of the ischemic 
liver may induce activation of complement. Activated products of the complement 
components have been detected in plasma after liver I/R of pigs and humans 
(Straatsburg et al. 2000; Bergamaschini et al. 2001). Depletion of serum complement 
before ischemia in rats has been shown to attenuate superoxide generation by 
Kupffer cells and the accumulation of neutrophils in the liver during I/R, thereby 
suppressing injury (Jaeschke et al. 1993). Inhibition of the complement cascade by 
soluble complement receptor type 1 (sCR1) after liver I/R significantly reduced 
endothelial complement C3 deposition and liver injury (Chavezcartaya et al. 1995). In 
addition, in the liver I/R model, endothelial cell integrity in the liver was preserved in 
transgenic mice overexpressing the human C1 inhibitor (Inderbitzin et al. 2004).  
 
There is accumulating evidence suggesting a role for complement system in the 
development of ALD. Contribution of C3 to the TG accumulation in the liver and 
significance of C5 in inflammation and injury have recently been demonstrated in C3-
/- and C5-/- mice fed the ethanol diet (Pritchard et al. 2007). 
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V   SUMMARY OF THE REVIEW 
 
A large body of evidence suggests a role for the complement system in injury and in 
repair processes. Complement system can trigger tissue damage by inflammation or 
contribute to homeostasis via clearance and disposal of injured cellular material. It is 
suggested that complement can also contribute to the development of alcoholic liver 
damage. We postulated that chronic ethanol consumption can disturb homeostasis of 
the complement system and thus complement activation is involved in the 
pathogenesis of ALD. TNF-α, ROS and LPS can injure hepatocytes and convert 
them into potential activators of complement. Ethanol can also lead to desialylation of 
protective glycoproteins on cell surface and activation of the AP. Loss of terminal 
sialic acid from carbohydrates could also lead to exposure of mannose or N-acetyl 
galactose, which can activate the LP of complement. Ethanol-induced proteins or 
lipid modifications could activate complement either directly or via formation of 
antibodies that can activate the CP. Ethanol can interact with soluble and membrane 
bound factors, such as FH, DAF, MCP and CD59. Loss of protection could lead to 
complement activation and tissue damage. 
 
Several important questions are still open. Damaging or protective functions of the 
complement system have been implicated in alcohol liver injury and what kind of 
complement-associated factors and molecular mechanisms are involved in the 
progression of ALD? Disturbances in the clearance and waste disposal functions of 
complement may be detrimental and could predispose complement-deficient 
individuals to alcohol-induced liver damage. Studying how C6 deficiency (in a C6-
deficient rat strain, which is unable to generate the MAC) affects experimental 
alcohol liver injury should increase our understanding of how the complement TP 
components interact with protective functions against alcohol in the liver. If 
complement activation contributes to ethanol-induced fatty liver, then mice lacking C3 
should be protected from ethanol-induced steatosis. By using a clinically relevant 
rodent model (C3-deficient knock-out mice) it is possible to examine the role of 
complement in ALD and the cellular regulatory activities and pathogenetic 
mechanisms that could sensitize the liver tissue to complement-mediated damage.  
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VI   AIMS OF THE STUDY 
 
Although ALD is recognized as a major and increasing world-wide health problem, its 
pathogenetic mechanisms are still poorly understood. The fact that only a minority of 
chronic alcohol abusers ever develop advanced ALD demonstrates that predisposing 
or disease promoting factors unrelated to ethanol metabolism must contribute to or 
participate in the development of ALD. The immune system participates in 
inflammatory reactions and elimination of invading foreign, apoptotic or injured cells. 
The present work was designed to clarify some of the immune mechanisms that are 
involved in the pathogenesis of ALD, with particular emphasis on the role of 
complement system, which is part of the both innate and acquired immune systems.  
 
 
The specific aims of the present study were: 
 
1. To analyse complement activation and complement component gene expression 
in livers of chronically ethanol-treated rodents. 
2. To study how the absence of the terminal complement pathway (C6 deficiency) 
affects development of alcoholic liver injury.  
3. To study how complement C3 deficiency affects alcohol-induced liver steatosis.  
4. To study how ethanol and C3 deficiency affect expression of genes associated 
with lipid metabolism. 
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VII   MATERIALS AND METHODS  
7.1.   Animals and experimental design  
 
Normal male PVG/c rats (C6+/+) and complement C6-deficient PVG/c rats (C6-/-) were 
used in study I. Twelve rats from both strains received ethanol containing (5%) high-
fat/low-carbohydrate liquid diet for 6 weeks (Lindros and Järveläinen 1998). Normal 
male C57BL/6 C3+/+ and C3-/- mice (Horst, the Netherlands) were used in studies II, 
III and IV. All mice received a diet based on a liquid diet protocol, further modified 
into a gel by addition of agar (Bykov et al. 2004). Twelve mice from both strains 
received ethanol contained diet for 6 weeks. Pair-fed controls received control diet. In 
an acute ethanol exposure experiment C57BL/6 and C3-/- mice were given one dose 
of ethanol (5g/kg; 20% solution) for four hours intragastrically.  
 
7.2.   Laboratory methods  
 
The table (Table 2) below lists the experimental methods used in this thesis with a 
reference by Roman numerals to the original publication in which they were 
described. 
 
Table 2. Method used in the thesis 
 
Method 
 
 
Publication 
  
Serum and liver adiponectin determination III 
Plasma and liver TNF-α and IL-10 assay I, III 
Fractionation of serum lipoproteins   III 
Serum phospholipid transfer protein (PLTP) activity assay III 
Determination of protein concentration III 
Serum apolipoprotein A-I (apoA-I) measurement III 
Blood ethanol measurement I, II 
Plasma alanine aminotransferase (ALT) assay I, II, III 
Liver triglyceride measurement I, II, III 
Liver malondialdehyde determination  I 
Examination of liver histopathology  I, II, III 
Immunofluorescence staining and microscopy I, III 
Total RNA isolation I, III, IV 
RT-PCR analysis  I, III, IV 
RT-PCR analysis (TaqMan protocol) III, IV 
Microarray gene expression assay III, IV 
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Analytical methods 
 
Plasma and liver adiponectin concentrations were measured by using a Quantikine 
ELISA kit (R&D Systems Inc., NY, USA), which recognizes both low- and high-
molecular weight adiponectin. Liver adiponectin was assayed from diluted (Calibrator 
Diluent; 1:1000) supernatants obtained after centrifugation of liver homogenates.  
Plasma TNF-α, IL-10 and PGE2 concentrations were measured by Quantikine ELISA 
kits (R&D Systems Inc., NY, USA). For liver cytokine assay about 200 mg frozen liver 
tissue was homogenized in 25 mM Hepes buffer and centrifuged at 20,000g for 
15 min at 4 °C. TNF-α and IL-10 levels in supernatant were measured by ELISA kits.  
Serum lipoproteins were fractionated by FPLC. For each group two or three 200 µl 
serum samples pooled from 4 mice were analyzed. Serum phospholipid transfer 
protein (PLTP) activity was measured using a radiometric assay and serum 
apolipoprotein A-I (apoA-I) levels by sandwich ELISA.  
The blood concentration of ethanol was measured by head-space gas 
chromatography. Plasma alanine aminotransferase (ALT) activity was assayed by 
commercial kit (Boehringer Mannheim, Germany). For assay of liver TG (as glycerol), 
1 ml of liver methanol-chloroform mixed homogenate was washed with sodium 
chloride, the resultant extract was dried and dissolved in 200 μl of tetraethyl 
ammoniumhydroxide/95% ethanol (1:28). After incubation at 60oC for 30 min the 
extracts were subjected to hydrolysis by mixing with 200 μl 50 mM HCl. Glycerol was 
measured enzymatically by using commercial kits (Boehringer-Mannheim, Germany). 
The liver concentration of malondialdehyde, an indicator of lipid peroxidation, was 
determined by the thiobarbituric method. 
 
Liver histopathology  
 
Formalin-fixed liver samples embedded in paraffin were cut in 6 μm sections and 
stained with hematoxylin/eosin. Liver pathology was evaluated blindly. Steatosis was 
graded from 0 - 5 as follows: 1 = < 20% of cells containing fat, 2 = 21 - 40%, 3 = 41 - 
60%, 4 = 61 - 80%, 5 = > 80%. Inflammatory cell infiltration was graded from 0 - 5 
and based on the average of 10 randomly selected low-power fields. A single 
inflammatory cell = 1 point; an inflammatory focus consisting of 2 - 5 cells = 3 points; 
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and an inflammatory focus of more than 5 cells = 5 points. The total pathology score 
was calculated from the sum of steatosis and inflammation scores. 
 
Immunofluorescence microscopy analysis 
 
Liver tissue samples for indirect immunofluorescence (IFL) microscopy were quickly 
frozen on dry ice. Frozen sections (6 μm) were fixed with cold (- 20°C) acetone for 10 
min.  Sections were washed 3 times with phosphate-buffered saline (PBS, pH 7.4) 
and incubated for 30 min at +22°C with the primary antibodies. After three washes 
with PBS the sections were incubated with green fluorescein Alexa Fluor 488 goat 
anti – rabbit IgG antibody or Alexa Fluor 546 red fluorescein goat anti–mouse IgG 
antibody (Molecular Probes, Inc, Eugene, OR, USA). The slides were mounted with 
Immumount (Shandon Lipshaw, Pittsburgh, PA, USA). Antisera against rat C1, C8, 
C9 and CD59 were obtained from Prof. B.P. Morgan (University of Wales College of 
Medicine, Cardiff, Wales). Anti-rat C3 and anti–rat albumin antisera were purchased 
from Cappel Corporation (Malvern, PA, USA) and anti-Crry antibody from 
Pharmingen (San Diego, CA, USA). To test for non-specific reactions, control 
experiments without primary antibody were performed or rabbit anti–rat albumin 
antibody was used. The sections were analyzed with an Olympus BX-50 
fluorescence microscope and photographed with a Hamamatsu Orca IIIm CCD-
camera (Hamamatsu Photonics K.K., Mamatutsu City, Japan) and Openlab software 
(Improvision Corporation, MA, USA). In the IFL analysis control incubations were 
done either by omitting the primary antibody, by using nonimmune sera or by using 
antisera with known specificities other than those of the first antibodies.  
 
RT-PCR analysis 
 
Total RNA was isolated from liver samples (30 mg) using an Rneasy® Mini kit 
(Qiagen GmbH, Hilden, Germany). RNA quality was estimated by using the RNA 
6000 Nano assay in the Agilent Bioanalyzer monitoring for ribosomal S28/S18 RNA 
ratio and the total concentration of RNA was determined spectrophotometrically 
(A260). First-strand cDNA was transcribed from 1 μg RNA using Promega´s Reverse 
Transcription system according to the manufactureris instructions (Madison, WI, 
USA). PCR was performed using a PTC-200 Peltier Termal cycler (MJ Research). 
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The PCR products were quantified by anion exchange HPLC and expressed relative 
to that of β-actin mRNA.  
 
In the experiments with microarray gene expression assay, changes in expression of 
selected genes were verified by real-time PCR analysis (TaqMan protocol, Applied 
Biosystems). First-strand cDNA was transcribed from 1 μg RNA (extracted as 
described above) using High-Capacity cDNA Archive Kit (Applied Biosystems) with 
random primers. The cDNA was used as a template for the subsequent PCR carried 
out in triplicate. The expression levels were analyzed using pre-designed TaqMan 
Gene Expression assays probes and the Applied Biosystems 7300 Real Time PCR 
System. Relative mRNA expression levels in each experiment were normalized 
against the expression level of the housekeeping 18S rRNA by the comparative Ct 
method and fold change values calculated according to the manufacturer’s 
instructions. 
 
Microarray gene expression assay  
 
Microarray transcript profiling was carried out at the Microarray Core Facility of the 
Medical Faculty, the University of Helsinki, on Affymetrix MOE-430A chips that 
contain over 22,600 probe sets including transcripts and variants from 14,484 well 
annotated mouse genes. Three arrays per group were probed, and each probe 
represented a pool of 3-4 animals. Two μg of total RNA was treated according to the 
conventional Affymetrix eukaryotic RNA labeling protocol. Fifteen μg of biotin labeled 
cRNA was fragmented according to the Affymetrix eukaryotic sample protocol. 
Hybridization, staining and washing was performed using the Affymetrix Fluidics 
Station 450 and Hybridization Oven 640 under standard conditions. Scanned images 
were analyzed with Affymetrix Microarray Suite 5 software. For each probe array, a 
per gene normalization was applied so that signal intensities were divided by the 
median intensity calculated using all 12 probe arrays, effectively centering the data 
around unity. Normalized values were then averaged over samples in each group and 
ratios of these were calculated. Data processing was carried out using GeneSpring 
6.1 data analysis software (Silicon Genetics, Redwood City, CA, USA). The genes 
were assigned to various groups according to their participation in cellular processes 
by using Gene Set Analysis Toolkit (http://bioinfo.vanderbilt.edu/webgestalt). 
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VIII   RESULTS AND DISCUSSION  
8.1. COMPLEMENT ACTIVATION AND MODULATION OF 
COMPLEMENT GENE EXPRESSION IN THE LIVER BY CHRONIC 
ETHANOL UPTAKE (I, III, IV) 
8.1.1.   The effect of ethanol on complement component deposition  
 
In order to study the effects of chronic ethanol intake on the complement system we 
examined the deposition of complement components in liver and expression of liver 
genes associated with the complement system in animals with alcohol-induced liver 
injury. A deposition of the complement components C1, C3, C8 and C9 was 
observed in the livers of alcohol-treated wild type rats (I; Figs 3 and 4). The same 
tendency was found with respect to component C3 in wild type mice, receiving 
prolonged ethanol treatment (III; Fig 1). In contrast, only minimal complement 
component deposition was found in livers from complement C6-deficient ethanol-fed 
rats. Complement regulators Crry and CD59 were expressed on hepatocyte cell 
membranes in both wild type and C6-deficient rats (I; Fig 3).  
 
Chronic alcohol intake can be considered as a continuous inflammatory stress. Many 
complement components belong to type II acute phase proteins that respond to 
inflammatory stimuli more slowly and with a smaller increase than type I acute phase 
proteins, like CRP. Increased levels of the early pathway complement components 
could thus contribute to inflammation and tissue damage. This would be in line with 
an increased hepatic deposition of complement components C1, C3, C8 and C9 in 
rats receiving a prolonged ethanol treatment (I, Järveläinen et al. 2002). The 
decrease in deposition of the examined complement components after ethanol 
treatment in livers of C6-/- rats was intriguing. While it is logical that C8 and C9 are not 
deposited in the livers of C6-/- animals, the decrease in C1q and C3 deposition could 
be due to the fact that in the absence of MAC less tissue debris is produced. 
Cell membrane injury caused by MAC is able to expose complement-activating 
intracellular structures such as mitochondrial membranes and intermediate filaments.  
 
Thus, in the C6+/+ rats the normal clearance function is operating and cytoskeletal 
deposition of C1 and C3 could indicate that injured tissue material is recognized. 
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 8.1.2.   The effect of ethanol on complement gene expression 
 
We analyzed how chronic ethanol intake affects the expression of hepatic genes of 
proteins associated with the complement system in wild type and C3-deficient (C3-/-) 
mice by microarray transcript profiling using Affymetrix MOE-430A mouse chips. As 
an overall trend we observed that alcohol exposure increased mRNA expression of 
components of both the AP and the CP. Chronic ethanol intake increased C3 mRNA 
expression in wild type mice (IV; Table 1). The expressions of transcripts for 
complement factor B, C1qB, C6 and factor I were lower in the livers of C3-/- mice as 
compared to wild type mice, while the opposite was true for factor D (adipsin) and 
Masp-2 (IV; Table 1, Figs 1-3). Ethanol up-regulated factor B, C1qA, C2 and 
clusterin genes, although the effect was significant only in wild type mice (IV; Table 
1, Figs 1 and 3). In C3-deficient mice ethanol up-regulated C1qB and vitronectin but 
down-regulated Masp-2 expression (IV; Figs 1 and 3, Table 1). It should be noted 
that ethanol down-regulated the expression of the soluble regulators factor H and 
C4bp but only in wild type mice (IV; Fig 3). Importantly, ethanol was found to down-
regulate the mRNA level of factor D, which is the least abundant, yet the rate-limiting 
enzyme in AP and the terminal complement components C6, C8α and C9 (IV; Table 
1, Fig 2). mRNA expression of the membrane-bound complement regulators MCP 
and CD59 was somewhat higher in C3-deficient than in wild type mice (IV; Table 1). 
Ethanol feeding slightly reduced the expression of MCP and CD59 in C3-/- mice and 
Crry in both genotypes.   
 
 
Microarray data further suggested an increased hepatic synthesis of C3 by ethanol. 
However, despite an increased synthesis, the enhanced deposition of C3 is most 
likely due to sequestering of C3 from the circulation and activation in the liver tissue, 
probably as a response to cellular damage by alcohol. Injured tissue components 
may covalently deposit C3b after local complement activation. Thus, an increased C3 
synthesis by ethanol could be indirect, induced by cytokines responding to increased 
LPS infiltration from the alcohol-induced “leaky” gut. This is supported by the fact that 
both LPS and IL-6 were found to up-regulate C3 gene expression in HepG2 cells 
(Wright et al. 2001). In addition, TNF-α has been found to up-regulate the expression 
and production of C3 in rat glomerular endothelial cells (Sheerin et al. 1997). 
However, in patients with alcoholic liver cirrhosis low plasma levels of the 
complement proteins C3 and C4 are commonly found (Calamita and Burini 1995). 
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 This might be attributed either to the hepatic disease itself, to ethanol action and/or to 
malnourishment of the patient. It should be noted that even an acute single 
intraperitoneal injection of ethanol could induce a selective and prolonged alteration 
in complement-mediated immune clearance, with a decrease in complement-
mediated sequestration of opsonized cells and in complement-dependent 
phagocytosis in mice (Messner et al. 1994). Chronic ethanol ingestion in mice is also 
associated with an initial decrease followed by a small rebound increase in 
complement-mediated clearance of injured cells (Messner et al. 1993).  
 
Ethanol treatment increased the expression of factor B, which plays an important role 
in the activation of the AP. The inflammatory cytokines, in particular TNF-α and IFN-
γ, are critical in regulating factor B gene expression in macrophages. LPS has been 
found to induce factor B promoter activity through the NF-kappa B cis-binding site 
(Huang et al. 2002). In contrast to factor B, ethanol markedly down-regulated the 
expression of factor D. This effect of ethanol on factor D could efficiently down-
modulate AP activity, unless the decreased synthesis in the liver is not compensated 
for by an increased factor D production in the adipose tissue. The disparate effects 
on factor B and factor D might reflect tissue-specific responses in the liver and fat 
cells. It is possible that down-regulation of factor D synthesis could also reflect effects 
of ethanol on fat cells. The high expression of factor D in C3-/- mice fed with high-fat 
diet, which caused marked liver fatty infiltration, is in accordance with the data on 
induction of components of the AP (сomplement C3, properdin and factor D) in the 
livers of mice fed with a fat diet (Recinos et al. 2004). Although factor D is the rate-
limiting enzyme of the AP it is not, unlike e.g. factor B and C3, consumed during AP 
activation. The changes in C3-/- mice receiving a high-fat diet were accompanied by a 
down-regulation of factor B. This notion is in line with the previous results on down-
regulation of hepatic transcription of factor B and its CP analogue C2 in animals on 
high-fat diet (Recinos et al. 2004). Overall our results indicate that the activity of AP 
is intimately related to lipid metabolism and influenced by alcohol. 
 
Chronic ethanol consumption also increased the expression of early CP components. 
It should be noted that C2 and factor B are homologous proteins (serine esterases), 
both encoded in the MHC class III region in chromosome 6. Ethanol regulated their 
expression in a similar manner. Of interest, LPS, IL-1 and TNF-α also increased C2 
synthesis in human fibroblasts (Kulics et al. 1994).   
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 Chronic ethanol intake down-regulated the expression of early pathway soluble 
component regulators (C4bp and factor H) in C3+/+ but not in C3-/- mice and 
increased the expression of TP regulators (clusterin and vitronectin). The lower 
expression of factor I in C3-/- mice may be a consequence of the C3 deficiency, since 
the C3b inactivating enzyme factor I is not needed. Reduced levels of complement 
regulators in C3+/+ mice would lead to an increased vulnerability to complement auto-
attack, particularly in the liver. By promoting complement activation alcohol could 
thus accelerate the progression of liver steatosis and inflammation. The reduced 
expression of the complement cell-membrane-bound regulators Crry and CD59 by 
ethanol is in line with our findings of a similar tendency of mRNA expression of these 
regulators, especially of Crry, which is essential in rodents in preventing complement 
attack (Järveläinen et al. 2002).  
 
Taken together, the results suggest that the induction of AP and CP components and 
suppression of TP components and soluble regulators by chronic ethanol 
consumption may contribute to alcohol-induced liver injury.  
 
 
 
8.2. ROLE OF THE COMPLEMENT TERMINAL PATHWAY IN 
ALCOHOL-INDUCED LIVER INJURY (I) 
8.2.1.   Effect of complement C6 deficiency on histopathological changes and 
parameters of liver function in alcohol-treated rats 
 
In order to evaluate whether an intact terminal pathway of the complement system 
aggravates or protects against alcohol-liver damage we compared the response to 
chronic ethanol feeding of rats genetically deficient in the complement component C6 
(C6-/-) with that of  wild type C6-sufficient (C6+/+) rats. C6 deficiency leads to an 
impaired assembly of MAC, and C6 and MAC have been shown to be involved in the 
development of various pathological conditions (Schmiedt et al. 1998; Nangaku et al. 
2002; Tran et al. 2002). Consequently, we investigated the role of the TP in the 
inflammatory consequences of chronic alcohol intake. We observed that chronic 
ethanol feeding resulted in a marked mixed micro- and macrovesicular steatosis and 
infiltration of mononuclear inflammatory cells in the livers of both C6+/+ and C6-/- 
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 animals (I; Fig 1). However, steatosis and inflammation were more prominent in C6-/- 
rats (I; Figs 1 and 2). The hepatic level of TG was also higher in C6-/- rats as 
compared to C6+/+ rats. The control C6-/- rats seemed to be more sensitive to the 
high-fat diet, as evidenced from significantly higher TG concentration and liver to 
body weight ratio as compared to C6+/+ controls. Changes in the plasma levels of 
liver ALT supported the histopathological findings; chronic alcohol feeding increased 
ALT values 12.5-fold in C6-/- and 6.5-fold in C6+/+ rats (I; Table 2). Thus, chronic 
ethanol intake in normal complement sufficient rats resulted in a marked steatosis 
and inflammatory cell infiltration and enhanced the hepatic deposition of complement 
components examined. In complement C6-deficient rats no corresponding 
complement activation was observed, but the parameters reflecting hepatic changes 
were more marked. This suggests that complement activation up to the level of the 
terminal pathway may be important in the repair of alcohol-induced lesions or in their 
regeneration, thus carrying out a protective function. 
 
A positive correlation between plasma C3 and liver enzyme elevations has been 
reported suggesting a role for complement activation in ALD (Bird et al. 1995). 
Complement activation is known to worsen the pathology of several disease states 
(Väkevä et al. 1993; Väkevä et al. 1995; Lindsberg et al. 1996; Väkevä et al. 1998). 
However, recently an important role of complement as a "clean-up" system has been 
suggested (Collard et al. 1999; Walport 2001 (a,b); McGeer and McGeer 2002). New 
evidence suggests that the complement system plays an essential role in liver 
regeneration. Upon partial hepatectomy C3- or C5-deficient mice exhibited high 
mortality, liver damage, and impaired liver regeneration (DeAngelis et al. 2006). In 
analogy to this, a continuous efficient regenerative repair process may be crucial in 
preventing the slow development of irreversible liver damage by chronic ethanol 
intake. Conceivably, injurious stimuli (endotoxin, oxygen free radicals, 
alcohol/acetaldehyde protein adducts, etc) would cause complement activation and 
mark injured cells for clearance by phagocytes. Complement deficiency could 
abrogate this function and prolong the inflammatory reaction. In the repair process 
MAC plays a crucial role in regulating apoptosis, cell proliferation and growth 
(Morgan 1989 (a,b); Väkevä et al. 1998; Soane et al. 1999; Rus et al. 2001; Zwaka et 
al. 2003). The number of membrane–inserted C5b-9 complexes determines whether 
complement activation promotes or prevents cell death. Thus, the level of 
complement activation could determine the pathophysiological fate of affected 
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 tissues and recovery of function in an inflammatory milieu (Rus et al. 2001). Sublytic 
amounts of MAC stimulate cells by activating phospholipases, protein kinase C and 
the production of inflammatory mediators, such as reactive oxygen metabolites, 
thromboxanes and prostaglandins (Morgan 1989 (a,b); Rus et al. 2001).  
 
Thus, while specific target cells, invading microbes or nonviable host cells often are 
destroyed by complement activation, the adjacent bystander cells may be saved and 
stimulated to respond to the local injury.  
 
 
8.2.2.   Effect of complement C6 deficiency on inflammatory responses in 
alcohol-treated rats 
 
In order to evaluate the effect of chronic ethanol on the inflammatory responses in 
C6-deficiency we measured the plasma levels and liver mRNA expression of 
cytokines. Chronic alcohol feeding led to a significant increase in the plasma 
concentration of TNF-α in C6-/- but not in C6+/+ rats (I; Table 2). In contrast, while 
ethanol significantly increased plasma IL-10 in C6+/+ rats it had no significant effect in 
C6-/- rats. Consequently, in alcohol fed rats, the plasma TNF-α/IL-10 ratio was 4 
times higher in C6-/- than in C6+/+ rats. Ethanol increased the mRNA expression of the 
CD14 and IL-10 in the livers equally well in C6+/+ and C6-/- rats (I; Table 3). After 
alcohol feeding the mRNA expression of TNF-α receptor-1 (TNFR1) was significantly 
higher in C6-/- than in C6+/+ rats. The plasma ratio of TNF-α and IL-10, which reflects 
the balance between pro- and anti-inflammatory cytokines, was closely associated 
with hepatic changes and correlated significantly with plasma ALT activity. IL-10 
produced mainly by Kupffer cells not only suppresses the production of pro-
inflammatory cytokines, but also down-regulates cytotoxicity of T-cells and the 
antigen-presenting function of sinusoidal endothelial cells (Moore et al. 1993; Knolle 
and Gerken 2000). The absence of an ethanol-induced increase in IL-10 levels in C6-
/- rats could thus be of pathogenetic importance. The lower level of the anti-
inflammatory IL-10 cytokine together with the increased TNF-α response to alcohol-
induced injury in C6-/- rats suggests that C6 deficiency leads to an impaired tissue 
clearance and a stronger inflammatory response.   
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 The observed difference in liver fat metabolism between C6-/- and C6+/+ rats 
prompted us also to investigate the effect of ethanol on prostanoid responses. 
Analysis of PGE2 from plasma did not reveal any significant effect of ethanol, nor was 
there any difference between C6-/- and C6+/+ rats. However, ethanol caused marked 
up-regulation of the mRNA expression of prostaglandin E EP2 (prostaglandin E 
receptor) (5.4-fold) and EP4 (8.4-fold) receptors in C6-/- animals (I; Table 4). In 
contrast, no significant up-regulation was seen in C6+/+ rats. PGE2 modulates the 
production of TNF-α by Kupffer cells and other macrophages by increasing the 
intracellular cAMP level through G-protein-coupled EP2 and EP4 receptors. The 
stronger up-regulation of these receptors in livers from ethanol-treated C6-/- rats 
suggests that complement C6 deficiency sensitizes the liver to pro-inflammatory 
cytokines. These effects may be associated with the more massive ethanol-induced 
steatosis and the higher TG concentration in control C6-/- than in C6+/+ rat livers. 
Indeed, Kupffer cells seem to play an important role in alcohol-induced steatosis, 
which sensitizes the liver to further damage (Enomoto et al. 2000; Stewart et al. 
2001).  
 
Thus, in animals with a deficient TP (C6-/-) parameters indicating alcohol-induced 
hepatic damage are more marked than in normal rats. This suggests that a 
malfunctioning response to injury predisposes to stronger inflammatory reactions and 
accelerates the development of injury. An intact terminal pathway of the complement 
system may have an important function in the prevention and/or repair of alcohol-
induced liver lesions. 
 
 
 
8.3. ROLE OF ALTERNATIVE COMPLEMENT PATHWAY IN 
ALCOHOL-INDUCED LIVER STEATOSIS (II, III) 
8.3.1.   Effect of complement C3 deficiency on histopathological changes, liver 
function and lipid parameters in alcohol-treated mice   
 
In order to investigate the role of complement in alcohol-induced steatosis and other 
signs of liver damage we analysed normal mice in comparison to mice lacking the C3 
complement component. The hepatic effects of both control and ethanol diet were 
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 clearly different between wild type C3+/+ and C3-/- mice. The high-fat diet by itself 
caused marked macrovesicular steatosis in C3-/- mice, in contrast to C3+/+ mice (II; 
Fig 1, Table 1). The strain-specific diet effect was also seen as a significantly 
increased level of TG in the liver (II; Fig 2). As a consequence, the relative liver 
weight was also higher in C3-/- than in C3+/+ mice and in animals on control diet, the 
serum ALT activity was significantly higher in C3-/- than in C3+/+ mice (II; Table 1, Fig 
2). In C3+/+ mice, the ethanol diet caused significant increases in liver steatosis, TG 
concentration and the liver/body weight ratio. Serum ALT activity and the 
concentration of MDA, which reflects lipid peroxidation, were doubled. In C3-/- mice, 
which received ethanol the steatosis score was even lower than in mice on ethanol-
free diet, and there was no effect of ethanol diet on liver TG.  
 
To elucidate whether the aberrant effect of ethanol on liver lipids in C3-/- mice was 
specific to the high-fat diet composition combined with chronic ethanol exposure, a 
separate study was undertaken. C3+/+ and C3-/- mice kept on chow diet were 
intragastrically intubated and given a single intoxicating dose of ethanol. Four hours 
later the concentration of TG in the liver had increased by 138% in the normal C3+/+ 
mice as compared to mice given water. In contrast, in livers of C3-/- mice the increase 
was only 64% (II; Fig 3). Thus, following both acute and chronic ethanol intake C3+/+ 
and C3-/- mice respond differently, implying a role for C3 and the complement system 
in regulating liver steatosis.  
 
Ethanol-induced fatty infiltration sensitizes the liver to subsequent inflammatory and 
necrotic changes (Lieber 2004). The inflammatory response includes activation of the 
complement system and generation of inflammation-inducing anaphylatoxins 
(Nielsen et al. 2000; Oksjoki et al. 2003; Ogden and Elkon 2006). The complement 
component C3 has been shown to affect lipid homeostasis via its cleavage product 
C3adesArg (acylation-stimulating protein, ASP) (Cianflone et al. 1999; Cianflone et al. 
2003). C3-deficient animals that cannot generate ASP exhibit a compromised 
regulation of adipocyte lipid storage and TG synthesis (Baldo et al. 1993; Murray et 
al. 1999). Consequently, the complement system may also be involved in the 
development of alcohol-induced steatosis. Our data that in C3 deficient mice ethanol 
exposure does not increase the accumulation of TG, a phenomenon normally seen in 
rodents as well as in man suggests that C3 contributes to ethanol-induced liver fatty 
infiltration (Stewart et al. 2001; Persson et al. 2004). Our data were supported by the 
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 recent observation that the C3-/- mice were protected against ethanol-mediated 
steatosis (Pritchard et al. 2007). Thus, an intact complement system, and especially 
the presence of C3, contributes to liver damage rather than being protective (II). This 
contribution to damage seems to be indirectly mediated via steatosis, which is 
considered to sensitize the liver to inflammatory attack. This concept is supported by 
our findings that in C3+/+ mice, but not in C3-/- mice, chronic ethanol administration 
increased serum ALT activity and liver MDA concentration. MDA is an indicator of the 
degree of lipid peroxidation, which gives rise to reactive oxygen radicals injurious to 
cells. The fact that C3 has a different and more central role in the complement 
cascade than C6 may explain why C6 deficiency seemed to aggravate rather than 
protect against damage.  
 
Thus our results suggest a dual role for the complement system where, on one hand, 
it contributes to inflammation and tissue damage and, on the other hand, participates 
in the clean-up process and tissue repair and/or regeneration.  
 
Many studies indicate that the AP of the complement system influences lipid 
metabolism. Thus, in patients with an antibody against the AP C3 convertase C3bBb, 
called C3 nephritic factor (C3Nef), partial lipodystrophy occasionally accompanies 
membranoproliferative glomerulonephritis type II (Sissons et al. 1976). C3Nef causes 
hypercatabolism of the AP and drastically lowers C3 levels (Misra et al. 2004). 
Hypercatabolism of C3 and consequent depletion of C3 thus seem to be related to 
redistribution of fat from peripheral tissue to the liver and the lower abdominal area.  
 
Complement C3 activation leads to the formation of C3a, which is subsequently 
converted to C3a/desarg, alias ASP, following removal of the C-terminal arginine. 
ASP has been suggested to participate in the clearance of postprandial TG and to 
promote uptake of free fatty acids to peripheral fat tissue. It is therefore possible that 
the absence of C3 and ASP reduces the risk for peripheral obesity but allows 
steatosis in the liver, as we have observed in our present mouse model. In the 
presence of ethanol, however, the situation seems to be somewhat different. In livers 
of the C3+/+ mice, but not in the C3-/- mice, ethanol increases fat accumulation and 
this is accompanied by more hepatotoxic and inflammatory changes. This suggests 
that an intact complement system contributes to these changes. Such changes could 
be a consequence of enhanced production of inflammatory signals by Kupffer cells 
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 activated by circulating LPS in response to ethanol. Although moderate activation of 
Kupffer cells can contribute to repairing injury, excessive activation may be 
detrimental and lead to aggravation of injury.  
 
Ethanol treatment increased steatosis and TG selectively in wild type mice (III; Table 
1). For several of the lipid and lipoprotein parameters analyzed, ethanol treatment 
caused similar changes in C3+/+ and C3-/- mice (III; Table 1). While ethanol had no 
significant effect on serum TG, serum total cholesterol levels and the activity of PLTP 
were significantly reduced in both genotypes. Analysis of the lipoprotein profiles 
suggested that ethanol reduced apoA-I levels in the eluted HDL fractions slightly 
more in C3+/+ (18%) than in C3-/- mice (6%). The different liver lipid response in C3+/+ 
and C3-/- mice prompted us to measure adiponectin from serum and liver. Liver 
adiponectin levels in animals on control high-fat diet were significantly lower in C3-/- 
than in C3+/+ mice (III; Fig 2). In C3+/+ mice ethanol reduced serum adiponectin 
levels, an effect that was more apparent after acute ethanol challenge (III; Fig 2). In 
contrast, in C3-/- mice chronic ethanol challenge increased the level of adiponectin 
both in serum and in the liver tissue. 
 
The significant increase by ethanol of serum and liver adiponectin concentration in 
C3-/- mice may thus contribute to the observed reduction in hepatic steatosis. The 
simultaneous down-regulation of adiponectin receptor 2 mRNA expression may 
represent a feed-back regulatory response to adiponectin (III, Fig 4). In C3 deficiency 
the ethanol-induced increase in adiponectin is accompanied by that of the 
homologous complement protein C1q B-chain, in a possible concerted response-to-
injury action. This response could have a protective function or a role in the 
clearance of lipid particles or injured cells. Adiponectin affects energy homeostasis 
and insulin sensitivity via activation of AMP kinase and PPAR-α, thus increasing lipid 
β-oxidation and decreasing tissue TG levels (Yamauchi et al. 2003). In Zucker rats 
high levels of adiponectin were associated with alleviated nonalcoholic fatty liver and 
reduced expression of TNF-α (Nagao et al. 2005). Adiponectin also has anti-
inflammatory actions and its therapeutic delivery reduces fatty liver disease in 
rodents (Xu et al. 2003; Thakur et al. 2006).  
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 8.3.2.   Effect of complement C3 deficiency on the expression of liver genes 
associated with lipid metabolism in alcohol-treated mice 
 
To better understand how complement C3 affects lipid metabolism during chronic 
alcohol exposure we analyzed expression of genes associated with lipid and 
lipoprotein metabolism by microarray transcript profiling. At the gene expression 
level, the effect of ethanol on apolipoproteins was similar in C3+/+ and C3-/- mice (III; 
Fig 3). The effects of ethanol treatment on the expression of genes of fatty acid 
metabolizing enzymes were in general similar in both genotypes (III; Table 2). 
Chronic ethanol intake increased the expression of acyl-CoA dehydrogenase, but 
down-regulated acetyl-carboxylase-beta, carnitine palmitoyltransferase I, acyl-CoA 
synthetase and hydroxyacyl-CoA dehydrogenase type II transcripts as well as two 
fatty acid binding proteins (III; Table 2). The hepatic expression of several other 
genes exhibited patterns reminiscent of the effect on fatty infiltration in C3-/- mice. 
Thus the expressions of both AdR2 and ADRP were significantly down-regulated by 
ethanol exclusively in C3-/- animals (III; Fig 4). The expression of SREBP-1 was 
significantly higher in C3-/- mice while ethanol significantly reduced PPAR-α mRNA 
exclusively in C3+/+ mice. As was observed at the protein level, reduction by ethanol 
feeding of mRNA for PLTP was similar in both genotypes (III; Fig 4). The expression 
of PLD1 was significantly reduced in C3-/- mice but this effect was counteracted by 
ethanol treatment. The expression of ADRP, a lipid droplet protein, was strongly 
induced in cells with increased lipid load. ADRP-deficient mice have reduced hepatic 
TG and resist diet-induced fatty liver, suggesting that ADRP is involved in TG 
deposition (Chang et al. 2006). Our finding that ADRP was significantly down-
regulated by ethanol only in C3-/- mice, with reduced steatosis, is consistent with this 
notion. The increased expression of SREBP-1 in C3-/- mice could be related to the 
steatotic effect of the diet in these mice. The SREBP-1c variant predominating in the 
liver is lipogenic and could act via up-regulation of FAS expression (Horton et al. 
2002; Eberlé et al. 2004). However, SREBP-1c does not seem to be critically 
involved in ethanol-induced steatosis here, since in contrast to an earlier report (You 
and Crabb 2004 (a)), ethanol had no significant effect on its expression in either 
strain.  
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 Our observation that ethanol down-regulated the mRNA expression of PPAR-α in 
C3+/+ but not in C3-/- mice may be of particular relevance. PPAR-α activation 
increases liver disposal of fatty acids and PPAR-α knock-out animals develop fatty 
liver and obesity (Costet et al. 1998; Kersten et al. 1999; Jump et al. 2005). 
Furthermore, ethanol feeding has been shown to compromise induction of PPAR-α-
regulated enzymes, thus contributing to the development of fatty liver (Fischer et al. 
2003). These data are in line with the present study, suggesting an important role of 
PPAR-α expression in the development of alcohol-induced liver steatosis.  
PLD1 is important in protein kinase C signaling and in the assembly of VLDL (Asp et 
al. 2000). This suggests the possibility that up-regulation of the PLD1 gene by 
ethanol in the C3-/- mice could enhance hepatic VLDL secretion, thus affecting the 
level of steatosis in these mice. 
 
The results indicate that the complement system is involved in the regulation of diet- 
and alcohol-induced fatty liver. Our observations in C3-/- animals support the notion 
that adiponectin, SREBP-1 and ADRP are important in lipid homeostasis, regulating 
fatty acid synthesis and uptake in the liver. Enhanced adiponectin levels, increased 
phospholipase D1 expression and reduced ADRP expression appear to protect 
against hepatic lipid deposition. Adiponectin may also, together with the complement 
component C1q, be involved in processing of lipid particles or materials released 
from injured cells. Ethanol intake leads to cell injury and complement C3-dependent 
steatosis with both direct and compensatory changes in several genes involved in 
lipid metabolism and clearance functions. 
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 IX   CONCLUDING REMARKS 
 
The studies described in this thesis demonstrate the involvement of the complement 
system in the development of inflammation and steatosis in alcoholic liver disease.  
 
To define the complement pathways involved, we investigated the expression of 
complement component and regulator gene transcripts by microarray analysis in the 
livers of alcohol-treated mice. Ethanol down-regulated mRNA levels of adipsin and of 
the TP complement components C6, C8α and C9. The up-regulation of complement 
factor B, C1qA, C2, C3 and clusterin and down-regulation of factor H and C4bp by 
ethanol was significant in wild type animals. These findings suggest that an induction 
of CP and AP and suppression of TP and complement regulator expression by 
chronic ethanol may be additional mechanisms of alcohol-induced liver injury. This 
would suggest an increased tendency for opsonophagocytosis and inflammation, and 
their possible involvement in the development of ALD. 
 
We also assessed the role of the TP in alcohol-induced liver damage in complement 
C6-deficient rats. Our results indicate that a deficient TP predisposes to tissue injury 
and promotes a pro-inflammatory cytokine response. The hepatic histopathological 
changes, the liver weight increase and the elevation of the plasma pro-/anti-
inflammatory cytokine ratio were more marked in C6-/- than in wild-type rats.  
 
Liver steatosis, a typical early consequence of alcohol exposure, sensitizes the liver 
to more severe inflammatory and fibrotic changes. On the other hand, activation of 
the key complement component C3, a central player in causing inflammation and 
tissue damage is also known to be involved in the regulation of lipid metabolism. This 
prompted us to study the development of alcoholic liver steatosis in mice lacking C3. 
Ethanol-containing diet caused marked macrovesicular steatosis and increased the 
liver TG level in C3+/+ mice. In contrast, ethanol diet tended to reduce steatosis and 
had no further effect on liver TG in C3-/- mice. This suggests that the complement 
system and particularly its component C3 contribute to the development of alcohol-
induced fatty liver. 
 
To understand the underlying molecular mechanisms of the involvement of C3 in 
ethanol-induced steatosis we analyzed lipid parameters and liver gene expression 
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 profiles in C3+/+ and C3-/- mice fed with an alcohol-liquid diet. Ethanol treatment 
increased serum and liver adiponectin levels but down-regulated transcripts of 
lipogenic enzymes, adiponectin receptor 2 and adipose differentiation-related protein 
and up-regulated phospholipase D1 exclusively in C3-/- mice. This suggests an 
important cross-talk between the complement system and lipid regulators in ethanol-
induced steatosis. We propose that these ethanol-induced alterations observed in 
C3-deficient mice contribute to protection against fatty infiltration and subsequent 
inflammatory processes in the livers of these mice.  
 
In summary, deposition of complement components C1, C3, C8 and C9 was 
observed in the livers of animals with alcohol-induced liver injury, and a deficient 
complement TP was found to predispose to tissue injury and promote a pro-
inflammatory cytokine response, whereas C3 deficiency contributed to protection 
against fatty infiltration. These findings may have implications for the therapy of 
alcohol-induced liver injury and its consequences. 
 
 
 
 
 
 51
 X   ACKNOWLEDGMENTS 
 
This work was carried out in the Department of Bacteriology and Immunology, 
University of Helsinki, Finland and Department of Mental Health and Alcohol 
Research at Public Health Institute during the years 2003-2007. This study was 
supported by grants from the Finnish Foundation for Alcohol Studies, the Academy of 
Finland and the Sigrid Jusélius Foundation. I would like to thank Professor Seppo 
Meri, Head of the Department of Bacteriology and Immunology and of the Haartman 
Institute, University of Helsinki and Professor Kalervo Kiinmaa from the Department 
of Mental Health and Alcohol Research at Public Health Institute for providing 
excellent research facilities. 
 
I am most grateful to my supervisor Professor Seppo Meri, for the welcome extended 
to me on becoming part of the team involved in this immunobiochemical research 
project. I am especially grateful for his guidance during this project where he 
exhibited outstanding professional expertise and exceptional knowledge in medicine 
and biology. 
 
I would also like to warmly thank my second supervisor docent Kai Lindros. He 
invited me to come to Finland to join his research on mechanisms of alcohol-induced 
liver injury. I have learned a lot from his expertise and I am grateful for his unfailing 
support and help in both scientific and non-scientific matters. I am delighted to say 
that our professional relationship developed into a close friendship. This has 
generated many nice memories including fishing trips to his summer cottage.  
 
My special thanks go to Professor Onni Niemelä and Docent Markku Viander for 
reviewing my thesis, for the constructive criticism and for giving valuable suggestions 
and positive comments for the improvement of this thesis and for Professor Laura 
Nagy for her kind promise to be my opponent. 
 
I warmly thank my collaborators and coauthors, especially Docent Matti Jauhiainen, 
Docent Vesa Olkkonen, Dr Harri Järveläinen, Dr Sirkku Saarikoski, Professor 
Christian Ehnholm for constructive and positive discussions, Dr Antti Väkevä for his 
expert help in immunohistochemistry staining and producing the digital images and 
Dr. Sami Junnikkala for the valuable contribution to this study.     
 
I want to thank Mr Massimilliano Gentile for his expertise in statistics, Dr. Elise Saario 
for her help in evaluating and documenting histopathology, Maria Andersson and Lea 
Puhakka for the expert technical assistance. I also want to thank all my colleagues 
and the personnel in the Department of Mental Health and Alcohol Research at 
Public Health Institute for their support and good company during this work and for 
always being so helpful and friendly. 
 
I am deeply grateful to my parents Leonid and Nina for support and encouragement 
during my life. I wish also thank to my relatives and friends for switching my thoughts 
away from science.  
 
Finally, I want to express my deepest thanks to my wife Anna and to our lovely 
children Leo and Maria for their love and continuous support during these years.  
 
Helsinki, 
Igor Bykov  
 
 52
 XI   REFERENCES  
 
1. Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG (1994) Inactivation of Kupffer 
cells prevents early alcohol-induced liver injury. Hepatology 20:453-460. 
2. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG (1995) Antibiotics prevent liver 
injury in rats following long-term exposure to ethanol. Gastroenterology 108:218-224. 
3. Ahearn JM and Fearon DT (1989) Structure and function of the complement receptors, 
CR1 (CD35) and CR2 (CD21). Adv Immunol 46:183-219. 
4. Ameratunga R, Winkelstein JA, Brody L (1998) Molecular analysis of the third 
component of canine complement (C3) and identification of the mutation responsible for 
hereditary canine C3 deficiency. J Immunol 160:2824-2830. 
5. Armendariz-Borunda J, Simkevich CP, Roy N, Raghow R, Kang AH, Seyer JM (1994) 
Activation of Ito cells involves regulation of AP-1 binding proteins and induction of type I 
collagen gene expression. Biochem J 304:817-824. 
6. Asp L, Claesson C, Boren J, Olofsson SO (2000) ADP-ribosylation factor 1 and its 
activation of phospholipase D are important for the assembly of very low-density 
lipoproteins. J Biol Chem 275:26285-26292. 
7. Atkinson JP and Goodship TH (2007) Complement factor H and the hemolytic uremic 
syndrome. J Exp Med 204:1245-1248.  
8. Auerbach HS, Burger R, Dodds AW, Colten HR (1990) Molecular basis of complement 
C3 deficiency in guinea-pigs. J Clin Invest 86:96-106. 
9. Bajaj M, Suraamornkul S, Piper P (2004) Decreased plasma adiponectin 
concentrations are closely related to hepatic fat content and hepatic insulin resistance 
in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200-206.  
10. Baldo A, Sniderman AD, St-Luce S, Avramoglu RK, Maslowska M, Hoang B (1993) The 
adipsin-acylation stimulating protein system and regulation of intracellular triglyceride 
synthesis. J Clin Invest 92:1543-1547. 
11. Bautista AP (2000) Impact of alcohol on the ability of Kupffer cells to produce 
chemokines and its role in alcoholic liver disease. J Gastroenterol Hepatol 15:349-356. 
12. Benzaquen LR, Nicholson-Weller A, Halperin JA (1994) Terminal complement proteins 
C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from 
endothelial cells. J Exp Med 179:985-992. 
13. Bergamaschini L, Gobbo G, Gatti S (2001) Endothelial targeting with C1-inhibitor 
reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin 
Exp Immunol 126:412-420.  
14. Bird GL, Lau JY, Davies ET, Williams RS (1995) Lack of plasma complement activation 
in severe acute alcoholic hepatitis. Alcohol Clin Exp Res 19:1537-1540. 
15. Blom AM, Villoutreix BO, Dahlbäck B (2004) Complement inhibitor C4b-binding protein-
friend or foe in the innate immune system? Mol Immunol 40:1333-1346. 
16. Bode C and Bode JC (2003) Effect of alcohol consumption on the gut. Best Pract Res 
Clin Gastroenterol 4:575-592. 
17. Bode C and Bode JC (2005) Activation of the innate immune system and alcoholic liver 
disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins 
induced by ethanol? Alcohol Clin Exp Res 29:166S-171S. 
 53
 18. Botto M and Walport MJ (2002) C1q, autoimmunity and apoptosis. Immunobiology 
205:395-406.  
19. Bourdi M, Eiras DP, Holt MP, Webster MR, Reilly TP, Welch KD, Pohl LR (2007) Role 
of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to 
acetaminophen-induced liver injury. Chem Res Toxicol 20:208-216. 
20. Brandt J, Pippin J, Schulze M (1996) Role of the complement membrane attack 
complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. 
Kidney Int 49:335-343.  
21. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C 
(1997) Adipose differentiation-related protein is an ubiquitously expressed lipid storage 
droplet-associated protein. J Lipid Res 38:2249-2263.  
22. Brauer RB, Baldwin WM 3rd, Daha MR, Pruitt SK, Sanfilippo F (1993) Use of C6-
deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac 
xenografts. J Immunol 151:7240-7248. 
23. Bykov I, Palmen M, Piirainen L, Lindros KO (2004) Oral chronic ethanol administration 
to rodents by agar gel diet. Alcohol Alcohol 39:499-502.  
24. Calamita Z and Burini RC (1995) Immunologic changes in alcoholic liver cirrhosis. Arq 
Gastroenterol 32:79-84. 
25. Campbell W, Okada N, Okada H (2001) Carboxypeptidase R is an inactivator of 
complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 
180:162-167.  
26. Cao Q, Mak KM, Lieber CS (2002) Dilinoleoylphosphatidylcholine decreases LPS-
induced TNFα generation in Kupffer cells of ethanol-fed rats: respective roles of MAPKs 
and NFκB. Biochem Biophys Res Commun 294:849-853.    
27. Carney DF, Koski CL, Shin ML (1985) Elimination of terminal complement 
intermediates from the plasma membrane of nucleated cells: the rate of disappearance 
differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of 
C5b-9. J Immunol 134:1804-1809. 
28. Chan RK, Ibrahim SI, Verna N, Carroll M, Moore FD Jr, Hechtman HB (2003) 
Ischaemia-reperfusion is an event triggered by immune complexes and complement. Br 
J Surg 90:1470-1478. 
29. Chang BH, Li L, Paul A, Taniguchi S, Nannegari V, Heird WC, Chan L (2006) 
Protection against fatty liver but normal adipogenesis in mice lacking adipose 
differentiation-related protein. Mol Cell Biol 26:1063-1076. 
30. Chavezcartaya RE, Pinodesola G, Wright L, Jamieson NV, White DJ (1995) Regulation 
of the complement cascade by soluble complement receptor type 1. Transplantation 
59:1047-1052. 
31. Chen JP, Ishac EJN, Dent P, Kunos G, Gao B (1998) Effects of ethanol on mitogen-
activated protein kinase and stress-activated protein kinase cascades in normal and 
regenerating liver. Biochem J 334:669-676.  
32. Choy LN, Rosen BS, Spiegelman BM (1992) Adipsin and an endogenous pathway of 
complement from adipose cells. J Biol Chem 267:12736-12741.  
33. Cianflone K, Maslowska M, Sniderman AD (1999) Acylation stimulating protein (ASP), 
an adipocyte autocrine: new directions. Semin Cell Dev Biol 10:31-41.  
 54
 34. Cianflone K, Xia Z, Chen LY (2003) Critical review of acylation-stimulating protein 
physiology in humans and rodents. Biochim Biophys Acta 1609:127-143. 
35. Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B (2005) C1 inhibitor: 
molecular and clinical aspects. Springer Semin Immunopathol 27:286-298. 
36. Cole DS and Morgan BP (2003) Beyond lysis: how complement influences cell fate. 
Clin Sci (Lond) 104:455-466. 
37. Cole JL, Housley GAJr, Dykman TR, MacDermott RP, Atkinson JP (1985) Identification 
of an additional class of C3-binding membrane proteins of human peripheral blood 
leukocytes and cell lines. Proc Natl Acad Sci USA 82:859-863.  
38. Collard CD, Lekowski R, Jordan JE, Agah A, Stahl GL (1999) Complement activation 
following oxidative stress. Mol Immunol 36:941-948. 
39. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T (1998) Peroxisome 
proliferator-activated receptor alpha-isoform deficiency leads to progressive 
dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273:29577-
29585. 
40. Cybulsky AV, Bonventre JV, Quigg RJ, Lieberthal W, Salant DJ (1990) Cytosolic 
calcium and protein kinase C reduce complement-mediated glomerular epithelial injury. 
Kidney Int 38:803-811.  
41. Cybulsky AV, Takano T, Papillon J, McTavish AJ (1999) Complement C5b-9 induces 
receptor tyrosine kinase transactivation in glomerular epithelial cells. Am J Pathol 
155:1701-1711.  
42. Daemen MA, van't Veer C, Denecker G (1999) Inhibition of apoptosis induced by 
ischemia-reperfusion prevents inflammation. J Clin Invest 104:541-549. 
43. Dalen KT, Ulven SM, Arntsen BM, Solaas K, Nebb HI (2006) PPARalpha activators and 
fasting induce the expression of adipose differentiation-related protein in liver. J Lipid 
Res 47:931-943.  
44. D'Ambrosio AL, Pinsky DJ, Connolly ES (2001) The role of the complement cascade in 
ischemia/reperfusion injury: implications for neuroprotection. Mol Med 7:367-382.  
45. Dashiell SM, Rus H, Koski CL (2000) Terminal complement complexes concomitantly 
stimulate proliferation and rescue of Schwann cells from apoptosis. Glia 30:187-198. 
46. Davies ME, Horner A, Loveland BE, Mckenzie IF (1994) Complement deficiency and 
immune complex disease. Springer Semin Immunopathol 15:397-416. 
47. Deaciuc IV, Doherty DE, Burikhanov R, Lee EY, Stromberg AJ, Peng X, de Villiers WJ 
(2004) Large-scale gene profiling of the liver in a mouse model of chronic, intragastric 
ethanol infusion. J Hepatol 40:219-227.  
48. DeAngelis RA, Markiewski MM, Lambris JD (2006) Liver regeneration: a link to 
inflammation through complement. Adv Exp Med Biol 586:17-34.  
49. Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H (2005) 
Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42:905-914.  
50. Denys A, Udalova IA, Smith C, Williams LM, Ciesielski CJ, Campbell J, Andrews C, 
Kwaitkowski D, Foxwell BM (2002) Evidence for a dual mechanism for IL-10 
suppression of TNF-alpha production that does not involve inhibition of p38 mitogen-
activated protein kinase or NF-kappa B in primary human macrophages. J Immunol 
168:4837-4845. 
 55
 51. Diehl AM (2005) Recent Events in Alcoholic Liver Disease V. Effects of ethanol on liver 
regeneration. Am J Physiol 288:G1-G6. 
52. Donohue TM Jr (2007) Alcohol-induced steatosis in liver cells. World J 
Gastroenterol 13:4974-4978. 
53. Eaton S, Record CO, Bartlett K (1997) Multiple biochemical effects in the pathogenesis 
of alcoholic fatty liver. Eur J Clin Invest 27:719-722.  
54. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F (2004) SREBP transcription 
factors: master regulators of lipid homeostasis. Biochimie 86:839-848. 
55. Ellison RT 3rd, Horsburgh CR Jr, Curd J (1990) Complement levels in patients with 
hepatic dysfunction. Dig Dis Sci 35:231-235. 
56. Emoto M, Emoto Y, Brinkmann V, Miyamoto M, Yoshizawa I, Stäber M, van Rooijen N, 
Hamann A, Kaufmann SH (2003) Increased resistance of LFA-1-deficient mice to 
lipopolysaccharide-induced shock/liver injury in the presence of TNF-alpha and IL-12 is 
mediated by IL-10: a novel role for LFA-1 in the regulation of the proinflammatory and 
anti-inflammatory cytokine balance. J Immunol 171:584-593. 
57. Enomoto N, Ikejima K, Yamashina S, Enomoto A, Nishiura T, Nishimura T, Brenner DA 
(2000) Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat 
accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol 279:G100-G106. 
58. Erhardt A, Biburger M, Papadopoulos T, Tiegs G (2007) IL-10, regulatory T cells, and 
Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice. 
Hepatology 45:475-485. 
59. Esser AF (1994) The membrane attack complex of complement: assembly, structure 
and cytotoxic activity. Toxicology 87:229-247. 
60. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) 
Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine 
production through autocrine/paracrine mechanisms involving TGF-b, PGE2, and PAF. 
J Clin Invest 101:890-898. 
61. Faraj M, Sniderman AD, Cianflone K (2004) ASP enhances in situ lipoprotein lipase 
activity by increasing fatty acid trapping in adipocytes. J Lipid Res 45:657-666. 
62. Fischer M, You M, Matsumoto M, Crabb DW (2003) Peroxisome proliferator-activated 
receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and 
abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 278:27997-
28004.   
63. Fishelson Z, Attali G, Mevorach D (2001) Complement and apoptosis. Mol Immunol 
38:207-219.  
64. Frank MM (2005) Hereditary angioedema. Curr Opin Pediatr 17:686-689. 
65. Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular 
response to tissue injury. J Biol Chem 275:2247-2250. 
66. Galli A, Pinaire J, Fischer M, Dorris R, Crabb DW (2001) The transcriptional and DNA 
binding activity of peroxisome proliferator-activated receptor α is inhibited by ethanol 
metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J 
Biol Chem 276:68-75.   
67. Gao J and Serrero G (1999) Adipose differentiation related protein (ADRP) expressed 
in transfected COS-7 cells selectively stimulates long chain fatty acid uptake. J Biol 
Chem 274:16825-16830.  
 56
 68. Garnier G, Circolo A, Colten HR (1996) Constitutive expression of murine complement 
factor B gene is regulated by the interaction of its upstream promoter with hepatocyte 
nuclear factor 4. J Biol Chem 271:30205-30211. 
69. Gregoire FM, Zhang Q, Smith SJ, Tong C, Ross D (2002) Diet-induced obesity and 
hepatic gene expression alterations in C57BL/6J and ICAM-1-deficient mice. Am J 
Physiol Endocrinol Metab 282:E703-E713.  
70. Gregory SH and Wing EJ (2002) Neutrophil-Kupffer cell interaction: a critical 
component of host defenses to systemic bacterial infections. J Leukocyte Biol 72:239-
248.  
71. Guo Z, Xia Z, Yuen V, McNeill J (2007) Cardiac expression of adiponectin and its 
receptors in streptozotocin-induced diabetic rats. Metabolism 56:1363-1371. 
72. Han DW (2002) Intestinal endotoxemia as a pathogenetic mechanism in liver failure. 
World J Gastroenterol 8:961-965. 
73. Hansch GM, Seitz M, Martinotti G, Betz M, Rauterberg EW, Gemsa D (1984) 
Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response 
to late complement components. J Immunol 133:2145-2150. 
74. Harada S, Agarwal DP, Nomura F, Higuchi S (2001) Metabolic and ethnic determinants 
of alcohol drinking habits and vulnerability to alcohol-related disorder. Alcohol Clin Exp 
Res 25:71S-75S. 
75. Harris CL, Rushmere NK, Morgan BP (1999) Molecular and functional analysis of 
mouse decay accelerating factor (CD55). Biochem J 341:821-829. 
76. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW (1998) Adipophilin is a 
specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue 
Res 294:309-321.  
77. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, 
Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J, Gressner AM, Matern S, 
Lammert F (2005) Complement factor 5 is a quantitative trait gene that modifies liver 
fibrogenesis in mice and humans. Nat Genet 37:835-843. 
78. Hines IN and Wheeler MD (2004) Recent Advances in Alcoholic Liver Disease III. Role 
of the innate immune response in alcoholic hepatitis Am J Physiol Gastrointest Liver 
Physiol 287:G310-G314.  
79. Hoek J, Thiele GM, Klassen LW, Mandrekar P, Zakhari S, Cook RT, Ray NB, Happel 
KI, Kolls JK, Kovacs EJ, Szab G (2006) RSA 2004: combined basic research satellite 
symposium-mechanisms of alcohol-mediated organ and tissue damage: inflammation 
and immunity and alcohol and mitochondrial metabolism: at the crossroads of life and 
death session one: alcohol, cellular and organ damage. Alcohol Clin Exp Res 29:1735-
1743. 
80. Hoek JB and Pastorino JG (2002) Ethanol, oxidative stress, and cytokine-induced liver 
cell injury. Alcohol 27:63-68. 
81. Hoek JB, Thomas AP, Rooney TA, Higashi K, Rubin E (1992) Ethanol and signal 
transduction in the liver. FASEB J 6:2386-2396.  
82. Høgåsen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M (1995) Hereditary porcine 
membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J 
Clin Invest 95:1054-1061. 
 57
 83. Holers VM, Kinoshita T, Molina H (1992) The evolution of mouse and human 
complement C3-binding proteins: divergence of form but conservation of function, 
Immunol Today 13:231-236.  
84. Homann C, Varming K, Hogasen K, Mollnes TE, Graudal N, Thomsen AC, Garred P 
(1997) Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to 
infection and increased mortality. Gut 40:544-549.  
85. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131. 
86. Horton JD, Shimomura I, Ikemoto S, Bashmakov Y, Hammer RE (2003) 
Overexpression of SREBP-1a in mouse adipose tissue produces adipocyte 
hypertrophy, increased fatty acid secretion, and fatty liver. J Biol Chem 278:36652-
36660.  
87. Horton JD and Shimomura I (1999) Sterol regulatory element-binding proteins: 
activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 10:143-150. 
88. Huang Y, Krein PM, Muruve DA, Winston BW (2002) Complement factor B gene 
regulation: synergistic effects of TNF-alpha and IFN-gamma in macrophages. J 
Immunol 169:2627-2635. 
89. Hui JM, Hodge A, Farrell GC (2004) Beyond insulin resistance in NASH: TNF-alpha or 
adiponectin? Hepatology 40:46-54.  
90. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG (1997) Antibodies to tumor 
necrosis factor-α attenuate hepatic necrosis and inflammation caused by chronic 
exposure to ethanol in the rat. Hepatology 26:1530-1537.  
91. Imai K, Nakajima K, Eguchi K (1991) Homozygous C3 deficiency associated with IgA 
nephropathy. Nephron 9:148-152. 
92. Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS (2007) Reduction 
of hepatosteatosis and lipid levels by an adipose differentiation-related protein 
antisense oligonucleotide. Gastroenterology 132:1947-1954.  
93. Imamura M, Inoguchi T, Ikuyama S, Taniguchi S, Kobayashi K, Nakashima N, Nawata 
H (2002) ADRP stimulates lipid accumulation and lipid droplet formation in murine 
fibroblasts. Am J Physiol Endocrinol Metab 283:E775-E783.  
94. Inderbitzin D, Beldi G, Avital I, Vinci G, Candinas D (2004) Local and remote ischemia-
reperfusion injury is mitigated in mice overexpressing human C1 inhibitor. Eur Surg Res 
36:142-147. 
95. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ (1993) Complement 
activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J 
Physiol 264:G801-G809. 
96. Järveläinen HA, Väkevä A, Lindros KO, Meri S (2002) Activation of complement 
components and reduced regulator expression in alcohol-induced liver injury in the rat. 
Clin Immunol 105:57-63.  
97. Järveläinen HA, Oinonen T, Lindros KO (1997) Alcohol-induced expression of the 
CD14 endotoxin receptor protein in rat Kupffer cells. Alcohol Clin Exp Res 21:1547-
1551. 
98. Järveläinen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO (2001) 
Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for 
alcoholic liver disease. Hepatology 33:1148-1153.  
 58
 99. Ji C and Kaplowitz N (2003) Betaine decreases hyperhomocysteinemia, endoplasmic 
reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 124:1488-1499. 
100. Johnstone RW, Loveland BE, McKenzie IF (1993) Identification and quantification of 
complement regulator CD46 on normal human tissues. Immunology 79:341-347.  
101. Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O (2005) Fatty acid 
regulation of hepatic gene transcription. J Nutr 135:2503-2506. 
102. Kamada Y, Tamura S, Kiso S (2003) Enhanced carbon tetrachloride-induced liver 
fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-1807.   
103. Kerr MA (1980) The human complement system: assembly of the classical pathway C3 
convertase. Biochem J 189:173-181.  
104. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W (1999) 
Peroxisome proliferator-activated receptor alpha mediates the adaptive response to 
fasting. J Clin Invest 103:489-498. 
105. Kishore R, Hill JR, McMullen MR, Frenkel J, Nagy LE (2002) ERK1/2 and Egr-1 
contribute to increased TNFα production in rat Kupffer cells after chronic ethanol 
feeding. Am J Phys 282:G6-G15. 
106. Kishore R, McMullen MR, Nagy LE (2001) Stabilization of TNFα mRNA by chronic 
ethanol: role of A + U rich elements and p38 mitogen activated protein kinase signaling 
pathway. J Biol Chem 276:41930-41937. 
107. Knolle PA and Gerken G (2000) Local control of the immune response in the liver. 
Immunol Rev 174:21-34.  
108. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, 
Yada R, Harada N, Takayanagi R, Nakamuta M (2007) Re-evaluation of fatty acid 
metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 
20:351-358. 
109. Koleva M, Schlaf G, Landmann R, Gotze O, Jungermann K, Schieferdecker HL (2002) 
Induction of anaphylatoxin C5a receptors in rat hepatocytes by lipopolysaccharide in 
vivo: mediation by interleukin-6 from Kupffer cells. Gastroenterology 122:697-708.  
110. Kono H, Bradford BU, Rusyn I, Fujii H, Matsumoto Y, Yin M, Thurman RG (2000) 
Development of an intragastric enteral model in the mouse: studies of alcohol-induced 
liver disease using knockout technology. J Hepatobiliary Pancreat Surg 7:395-400. 
111. Korb LC and Ahearn JM (1997) C1q binds directly and specifically to surface blebs of 
apoptotic human keratinocytes: complement deficiency and systemic lupus 
erythematosus revisited. J Immunol 158:4525-4528. 
112. Koteish A, Diehl AM (2001) Animal models of steatosis. Semin Liver Dis 21:89-104. 
113. Koteish A, Yang S, Lin H, Huang X, Diehl AM (2002) Chronic ethanol exposure 
potentiates lipopolysaccharide liver injury despite inhibiting Jun N-terminal kinase and 
caspase 3 activation. J Biol Chem 277:13037-13044.  
114. Kulics J, Circolo A, Strunk RC, Colten HR (1994) Regulation of synthesis of 
complement protein C4 in human fibroblasts: cell- and gene-specific effects of 
cytokines and lipopolysaccharide. Immunology 82:509-515. 
115. Lambris JD (1988) The multifunctional role of C3. The third component of complement. 
Immunol Today 9:387-393. 
116. Larigauderie G, Furman C, Jaye M, Lasselin C, Copin C, Fruchart JC, Castro G, Rouis 
M (2004) Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 
 59
 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol 24:504-
510.  
117. Latvala J, Hietala J, Koivisto H, Järvi K, Anttila P, Niemelä O (2005) Immune 
Responses to Ethanol Metabolites and Cytokine Profiles Differentiate Alcoholics with or 
without Liver Disease. Am J Gastroenterol 100:1303-1310. 
118. Lawrence T, Willoughby DA, Gilroy DW (2002) Anti-inflammatory lipid mediators and 
insights into the resolution of inflammation. Nat Rev 2:787-795.  
119. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW (1995) Targeted disruption of the alpha 
isoform of the peroxisome proliferator-activated receptor gene in mice results in 
abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012-
3022.  
120. Lee YJ, Aroor AR, Shukla SD (2002) Temporal activation of p42/44 mitogen-activated 
protein kinase and c-Jun N-terminal kinase by acetaldehyde in rat hepatocytes and its 
loss after chronic ethanol exposure. J Pharmacol Exp Ther 301:908-914. 
121. Lee A, Whyte MK, Haslett C (1993) Inhibition of apoptosis and prolongation of 
neutrophil functional longevity by inflammatory mediators. J Leukocyte Biol 54:283-288 
122. Lehner PJ, Davies KA, Walport MJ, Cope AP, Wurzner R, Orren A, Morgan BP (1992) 
Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion 
on lipopolysaccharide release. Lancet 340:1379-1381. 
123. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM (1993) Mouse Crry/p65. 
Characterization of monoclonal antibodies and the tissue distribution of a functional 
homologue of human MCP and DAF. J Immunol 151:4295-4305.  
124. Li XK, Fujino M, Guo L, Okuyama T, Funeshima N (2000) Inhibition of Fas-mediated 
fulminant hepatitis in CrmA gene-transfected mice. Biochem Biophys Res Commun 
273:101-109. 
125. Lieber CS (1991) Alcohol and fibrogenesis. Alcohol Alcohol 1:339-344. 
126. Lieber CS (2000) Alcohol: its metabolism and interaction with nutrients. Annu Rev Nutr 
20:395-430. 
127. Lieber CS (2004) Alcoholic fatty liver: its pathogenesis and mechanism of progression 
to inflammation and fibrosis. Alcohol 34:9-19. 
128. Lindros KO and Järveläinen HA (1998) A new oral low-carbohydrate alcohol liquid diet 
producing liver lesions: a preliminary account. Alcohol Alcohol 33:347-353. 
129. Lindsberg PJ, Ohman J, Lehto T, Karjalainen-Lindsberg ML, Paetau A, Wuorimaa T, 
Carpen O, Kaste M, Meri S (1996) Complement activation in the central nervous 
system following blood-brain barrier damage in man. Ann Neurol 40:587-596. 
130. Liszewski MK, Post TW, Atkinson JP (1991) Membrane cofactor protein (MCP or 
CD46): newest member of the regulators of complement activation gene cluster. Annu 
Rev Immunol 9:431-455. 
131. Lopez-Bermejo A, Botas P, Funahashi T (2004) Adiponectin, hepatocellular dysfunction 
and insulin sensitivity. Clin Endocrinol (Oxf) 60:256-263. 
132. Lublin DM and Atkinson JP (1989) Decay-accelerating factor: biochemistry, molecular 
biology, and function. Annu Rev Immunol 7:35-58. 
133. Lukkari TA, Järveläinen HA, Oinonen T, Kettunen E, Lindros KO (1999) Short-term 
ethanol exposure increases the expression of Kupffer cell CD14 receptor and 
lipopolysaccharide binding protein in rat liver. Alcohol Alcohol 34:311-319. 
 60
 134. MacSween RN and Burt AD (1986) Histologic spectrum of alcoholic liver disease. 
Semin Liver Dis 6:221-232.  
135. Markiewski MM, Mastellos D, Tudoran R, DeAngelis RA, Strey CW, Franchini S, 
Wetsel RA, Erdei A, Lambris JD (2004) C3a and C3b activation products of the third 
component of complement (C3) are critical for normal liver recovery after toxic injury. J 
Immunol 173:747-754. 
136. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M (2004) Adiponectin 
protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese 
mice. Hepatology 40:177-184.  
137. Mastellos D, Papadimitriou JC, Franchini S, Tsonis PA, Lambris JD (2001) A novel role 
of complement: mice deficient in the fifth component of complement (C5) exhibit 
impaired liver regeneration. J Immunol 166:2479-2486.  
138. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004) Adiponectin and metabolic 
syndrome. Arterioscler Thromb Vasc Biol 24:29-33.     
139. Maves KK and Weiler JM (1993) Properdin: approaching four decades of research. 
Immunol Res 12:233-243. 
140. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D (1999) Cytokines in alcoholic liver 
disease. Semin Liver Dis 19:205-219.    
141. McDonald JF and Nelsestuen GL (1997) Potent inhibition of terminal complement 
assembly by clusterin: characterization of its impact on C9 polymerization. Biochemistry 
36:7464-7473. 
142. McGeer PL and McGeer EG (2002) The possible role of complement activation in 
Alzheimer disease. Trends Mol Med 8:519-523.  
143. McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, Schlimgen R, Lee 
E, Foster B, Flemming D, Prussin C, Fleisher TA, Boumpas DT (2001) IL-10 improves 
skin disease and modulates endothelial activation and leukocyte effector function in 
patients with psoriatic arthritis. J Immunol 167:4075-4082. 
144. Mead R, Hinchliffe SJ, Morgan BP (1999) Molecular cloning, expression and 
characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). 
Immunology 98:137-143. 
145. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ 
(1990) Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting 
factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1-9.  
146. Messner RP, Meryhew NL, DeMaster EG (1994) Selective, prolonged alteration of 
complement-mediated immune clearance after acute exposure of mice to ethanol. Clin 
Immunol Immunopathol 70:73-80. 
147. Messner RP, Meryhew NL, DeMaster EG (1993) Effect of ethanol on immune 
clearance in mice: biphasic alteration of complement-mediated clearance with chronic 
ethanol ingestion. J Lab Clin Med 122:506-517. 
148. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent 
clearance of apoptotic cells by human macrophages. J Exp Med 188:2313-2320. 
149. Misra A, Peethambaram A, Garg A (2004) Clinical features and metabolic and 
autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and 
review of the literature. Medicine 83:18-34.  
 61
 150. Miwa T and Song WC (2001) Membrane complement regulatory proteins: insight from 
animal studies and relevance to human diseases. Int Immunopharmacol 1:445-459. 
151. Miwa T, Nonaka M, Okada N, Wakana S, Shiroishi T, Okada H (1998) Molecular 
cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential 
expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal 
chromosome 1. Immunogenetics 48:363-371. 
152. Mohan C, Adams S, Stanik V, Datta SK (1993) Nucleosome: a major immunogen for 
pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177:1367-1381. 
153. Mold C, Gewurz H, Du Clos TW (1999) Regulation of complement activation by C-
reactive protein. Immunopharmacology 42:23-30. 
154. Monsinjon T, Richard V, Fontaine M (2001) Complement and its implications in cardiac 
ischemia/reperfusion: strategies to inhibit complement. Fundam Clin Pharmacol 
15:293-306. 
155. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the 
interleukin-10 receptor. Annu Rev Immunol 19:683-765. 
156. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-
10. Annu Rev Immunol 11:165-190. 
157. Morgan BP and Gasque P (1997) Extrahepatic complement biosynthesis: where, when 
and why? Clin Exp Immunol 107:1-7.   
158. Morgan BP (1989) (a) Complement membrane attack on nucleated cells: resistance, 
recovery and non-lethal effects. Biochem J 264:1-14. 
159. Morgan BP (1989) (b) Mechanisms of tissue damage by the membrane attack complex 
of complement. Compl Inflamm 6:104-111.  
160. Morgan BP, Dankert JR, Esser AF (1987) Recovery of human neutrophils from 
complement attack: removal of the membrane attack complex by endocytosis and 
exocytosis. J Immunol 138:246-253.  
161. Morris KM, Aden DP, Knowles BB, Colten HR (1982) Complement biosynthesis by the 
human hepatoma-derived cell line HepG2. J Clin Invest 70:906-913. 
162. Motomura W, Inoue M, Ohtake T, Takahashi N, Nagamine M, Tanno S, Kohgo Y, 
Okumura T (2006) Up-regulation of ADRP in fatty liver in human and liver steatosis in 
mice fed with high fat diet. Biochem Biophys Res Commun 340:1111-1118.  
163. Mukherjee P and Pasinetti GM (2001) Complement anaphylatoxin C5a neuroprotects 
through mitogen-activated protein kinase-dependent inhibition of caspase 3. J 
Neurochem 77:43-49. 
164. Munoz LE, De Villiers D, Markham D, Whaley K, Thomas HC (1982) Complement 
activation in chronic liver disease. Clin Exp Immunol 47:548-554. 
165. Murray I, Sniderman AD, Cianflone K (1999) Enhanced triglyceride clearance with 
intraperitoneal human acylation stimulating protein in C57BL/6 mice. Am J Physiol 
277:E474-E480. 
166. Nagao K, Inoue N, Wang YM, Shirouchi B, Yanagita T (2005) Dietary conjugated 
linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Nutr 
135:9-13. 
167. Nagy LE (2003) Recent insights into the role of the innate immune system in the 
development of alcoholic liver disease. Exp Biol Med (Maywood) 228:882-890. 
 62
 168. Nagy LE (2004) Molecular aspects of alcohol metabolism: transcription factors involved 
in early ethanol-induced liver injury. Annu Rev Nutr 24:55-78. 
169. Nangaku M, Pippin J, Couser WG (2002) C6 mediates chronic progression of 
tubulointerstitial damage in rats with remnant kidneys. J Am Soc Nephrol 13:928-936. 
170. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, Johnson RJ, 
Couser WG (1997) Renal microvascular injury induced by antibody to glomerular 
endothelial cells is mediated by C5b-9. Kidney Int 52:1570-1578. 
171. Nanji AA, Tsukamoto H, French SW (1989) Relationship between fatty liver and 
subsequent development of necrosis, inflammation and fibrosis in experimental 
alcoholic liver disease. Exp Mol Pathol 51:141-148. 
172. Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T (1993) Severity of liver injury in 
experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin 
E2, leukotriene B4, and thromboxane B2. Am J Pathol 142:367-373. 
173. Nauta AJ, Daha MR, van Kooten C, Roos A (2003) Recognition and clearance of 
apoptotic cells: a role for complement and pentraxins. Trends Immunol 24:148-154. 
174. Nieto N (2006) Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells 
on stellate cells. Hepatology 44:1487-1501. 
175. Nickells MW, Atkinson JP (1990) Characterization of CR1- and membrane cofactor 
protein-like proteins of two primates. J Immunol 144:4262-4268. 
176. Niculescu F and Rus H (1999) Complement activation and atherosclerosis. Mol 
Immunol 36:949-955. 
177. Niculescu F, Badea T, Rus H (1999) Sublytic C5b-9 induces proliferation of human 
aortic smooth muscle cells: role of mitogen activated protein kinase and 
phosphatidylinositol 3-kinase. Atherosclerosis 142:47-56.  
178. Nielsen CH, Fischer EM, Leslie RG (2000) The role of complement in the acquired 
immune response. Immunology 100:4-12. 
179. Niemelä O, Parkkila S, Ylä-Herttuala S, Villanueva J, Ruebner B, Halsted CH (1995) 
Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig 
model of alcohol-induced liver disease. Hepatology 22:1208-1214. 
180. Nilsson UR and Müeller-Eberhard HJ (1965) Isolation of BETA IF-globulin from human 
serum and its characterization as the fifth component of complement. J Exp Med 
122:277-298. 
181. Ogden CA and Elkon KB (2006) Role of complement and other innate immune 
mechanisms in the removal of apoptotic cells. Curr Dir Autoimmun 9:120-142.  
182. Ogden CA, deCathelineau A, Hoffmann PR (2001) C1q and mannose binding lectin 
engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake 
of apoptotic cells. J Exp Med 194:781-795. 
183. Oksjoki R, Kovanen PT, Pentikainen MO (2003) Role of complement activation in 
atherosclerosis. Curr Opin Lipidol 14:477-482.  
184. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1977) Human complement C3b 
inactivator: isolation, characterization, and demonstration of an absolute requirement 
for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 
146:257-270. 
 63
 185. Pangburn MK, Müller-Eberhard HJ (1986) The C3 convertase of the alternative 
pathway of human complement. Enzymic properties of the bimolecular proteinase. 
Biochem J 235:723-730. 
186. Park PH, Thakur V, Pritchard MT, McMullen MR, Nagy LE (2006) Regulation of Kupffer 
cell activity during chronic ethanol exposure: role of adiponectin. J Gastroenterol 
Hepatol 21:S30-S33. 
187. Paul MS, Aegerter M, O'Brien SE, Kurtz CB, Weis JH (1989) The murine complement 
receptor gene family. Analysis of mCRY gene products and their homology to human 
CR1. J Immunol 142:582-589.  
188. Peng H, Takano T, Papillon J, Bijian K, Khadir A, Cybulsky AV (2002) Complement 
activates the c-Jun N-terminal kinase/stress-activated protein kinase in glomerular 
epithelial cells. J Immunol 169:2594-2601. 
189. Persson L,  Boren J,  Robertson AK,  Wallenius V,  Hansson GK, Pekna M (2004) Lack 
of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis 
in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc 
Biol 24:1062-1067. 
190. Phillips DJ, Novinger MS, Evatt BL, Hooper WC (1996) TNF-alpha suppresses IL-1 
alpha and IL-6 upregulation of C4b-binding protein in HepG-2 hepatoma cells. Thromb 
Res 81:307-314. 
191. Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple 
sclerosis. Nat Med (NY) 6:67-70. 
192. Pontoglio M, Pausa M, Doyen A, Viollet B, Yaniv M, Tedesco F (2001) Hepatocyte 
nuclear factor 1alpha controls the expression of terminal complement genes. J Exp 
Med 194:1683-1689. 
193. Powell MB, Marchbank KJ, Rushmere NK, van den Berg CW, Morgan BP (1997) 
Molecular cloning, chromosomal localization, expression, and functional 
characterization of the mouse analogue of human CD59. J Immunol 158:1692-1702.  
194. Preissner KT and Seiffert D (1998) Role of vitronectin and its receptors in haemostasis 
and vascular remodeling. Thromb Res 89:1-21. 
195. Pritchard MT, McMullen MR, Stavitsky AB, Cohen JI, Lin F, Medof ME, Nagy LE  
(2007) Differential contributions of C3, C5, and decay-accelerating factor to ethanol-
induced fatty liver in mice. Gastroenterology 132:1117-1126. 
196. Puschel GP,  Hespeling U,  Oppermann M, Dieter P (1993) Increase in prostanoid 
formation in rat liver macrophages (Kupffer cells) by human anaphylatoxin C3a. 
Hepatology 18:1516-1521.                                   
197. Qian YM, Qin X, Miwa T, Sun X, Halperin JA, Song WC (2000) Identification and 
functional characterization of a new gene encoding the mouse terminal complement 
inhibitor CD59. J Immunol 165:2528-2534.  
198. Qin X, Miwa T, Aktas H, Gao M, Lee C, Qian YM, Morton CC, Shahsafaei A, Song WC, 
Halperin JA (2001) Genomic structure, functional comparison, and tissue distribution of 
mouse Cd59a and Cd59b. Mamm Genome 12:582-589. 
199. Qin X and Gao B (2006) The complement system in liver diseases. Cell Mol Immunol 3: 
333-340.   
200. Recinos A 3rd, Carr BK, Bartos DB, Boldogh I, Carmical JR, Belalcazar LM, Brasier AR 
(2004) Liver gene expression associated with diet and lesion development in 
 64
 atherosclerosis-prone mice: induction of components of alternative complement 
pathway. Physiol Genomics 19:131-142.   
201. Reddy JK (2001) Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-
oxidation, PPAR α, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 
281:G1333-1339.  
202. Ripoche J, Day AJ, Harris TJR, Sim RB (1988) The complete amino acid sequence of 
human complement factor H. Biochem J 249:593-602. 
203. Rossi V, Cseh S, Bally I, Thielens NM, Jensenius JC, Arlaud GJ (2001) Substrate 
specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -
2. J Biol Chem 276:40880-40887. 
204. Rus H, Niculescu F, Shin M (2001) Role of C5b-9 complement complex in cell cycle 
and apoptosis. Immunol Rev 180:49-55. 
205. Rus H, Cudrici C, David S, Niculescu F (2006) The complement system in central 
nervous system diseases. Autoimmunity 39:395-402. 
206. Sato T, Van Dixhoorn MG, Prins FA, Mooney A, Verhagen N, Muizert Y, Savill J, Van 
Es LA, Daha MR (1999) The terminal sequence of complement plays an essential role 
in antibody-mediated renal cell apoptosis. J Am Soc Nephrol 10:1242-1252.  
207. Savill J and Fadok V (2000) Corpse clearance defines the meaning of cell death. 
Nature (London) 407:784-788. 
208. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR (2005) PPARgamma2 regulates 
lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol 
Metab 288:E1195-E1205.  
209. Schafer C, Parlesak A, Schutt C, Bode JC, Bode C (2002) Concentrations of 
lipopolysaccharide-binding protein, bactericidal/permeability-increasing protein, soluble 
CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver 
disease. Alcohol Alcohol 37:81-86.  
210. Schieferdecker HL,  Rothermel E,  Timmermann A,  Gotze O, Jungermann K (1997) 
Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells 
and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. 
FEBS Lett 406:305-309. 
211. Schieferdecker HL, Schlaf G, Jungermann K, Gotze O (2001) Functions of 
anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and 
parenchymal cells. Int Immunopharmacol 1:469-481.  
212. Schlaf G, Schmitz M, Heine I, Demberg T, Schieferdecker HL, Gotze O (2004) 
Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by 
anaphylatoxin C5a in rat hepatic stellate cells. Histol Histopathol 19:1165-1174. 
213. Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, Oelert H (1998) 
Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. 
Arterioscler Thromb Vasc Biol 18:1790-1795. 
214. Schwaeble W, Dahl MR, Thiel S, Stover C, Jensenius JC (2002) The mannan-binding 
lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin 
pathway activation complex encoded by two genes. Immunobiology 205:455-466. 
215. Scolding NJ, Morgan BP, Houston WA, Linington C, Campbell AK, Compston DA 
(1989) Vesicular removal by oligodendrocytes of membrane attack complexes formed 
by activated complement. Nature (London) 339:620-622. 
 65
 216. Shapiro L and Scherer PE (1998) The crystal structure of a complement-1q family 
protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8:335-338. 
217. Sheerin NS, Zhou W, Adler S, Sacks SH (1997) TNF-alpha regulation of C3 gene 
expression and protein biosynthesis in rat glomerular endothelial cells, Kidney Int 
51:703-710. 
218. Shimomura I, Bashmakov Y, Horton JD (1999) Increased levels of nuclear SREBP-1c 
associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 
274:30028-30032. 
219. Sim RB, Day AJ, Moffatt BE, Fontaine M (1993) Complement factor I and cofactors in 
control of complement system convertase enzymes. Methods Enzymol 223:13-35. 
220. Sim RB and Laich A (2000) Serine proteases of the complement system. Biochem Soc 
Trans 28:545-550.  
221. Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N, Peters DK (1976) 
The complement abnormalities of lipodystrophy. N Engl J Med 294:461-465.  
222. Smith SA (2002) Peroxisome proliferator-activated receptors and the regulation of 
mammalian lipid metabolism. Biochem Soc Trans 30:1086-1090. 
223. Soane L, Rus H, Niculescu F, Shin ML (1999) Inhibition of oligodendrocyte apoptosis 
by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by 
inhibition of caspase-3 activation. J Immunol 163:6132-6138. 
224. Song WC, Deng C, Raszmann K, Moore R, Newbold R, McLachlan JA, Negishi M 
(1996) Mouse decay-accelerating factor: selective and tissue-specific induction by 
estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J 
Immunol 157:4166-4172. 
225. Song WC (2004) Membrane complement regulatory proteins in autoimmune and 
inflammatory tissue injury. Curr Dir Autoimmun 7:181-199. 
226. Spicer AP, Seldin MF, Gendler SJ (1995) Molecular cloning and chromosomal 
localization of the mouse decay-accelerating factor genes. Duplicated genes encode 
glycosylphosphatidylinositol-anchored and transmembrane forms. J Immunol 155:3079-
3091.  
227. Stapp JM, Sjoelund V, Lassiter HA, Feldhoff RC, Feldhoff PW (2005) Recombinant rat 
IL-1beta and IL-6 synergistically enhance C3 mRNA levels and complement component 
C3 secretion by H-35 rat hepatoma cells. Cytokine 30:78-85. 
228. Stewart S, Jones D, Day CP (2001) Alcoholic liver disease: new insights into 
mechanisms and preventative strategies. Trends Mol Med 7:408-413. 
229. Straatsburg IH, Boermeester MA, Wolbink GJ, van Gulik TM, Gouma DJ, Frederiks 
WM, Hack CE (2000) Complement activation induced by ischemia-reperfusion in 
humans: a study in patients undergoing partial hepatectomy. J Hepatol 32:783-791. 
230. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE (2003) 
The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp 
Med 198:913-923. 
231. Su GL, Rahemtulla A, Thomas P, Klein RD, Wang SC, Nanji AA (1998) CD14 and 
lipopolysaccharide-binding protein expression in a rat model of alcoholic liver disease. 
Am J Pathol 152:841-849.  
 66
 232. Takano T, Cybulsky AV, Yang X, Aoudjit L (2001) Complement C5b-9 induces 
cyclooxygenase-2 gene transcription in glomerular epithelial cells. Am J Physiol Renal 
Physiol 281:F841-F850.  
233. Takizawa F, Tsuji S, Nagasawa S (1996) Enhancement of macrophage phagocytosis 
upon iC3b deposition on apoptotic cells. FEBS Lett 397:269-272. 
234. Tenner AJ, Volkin DB (1986) Complement subcomponent C1q secreted by cultured 
human monocytes has subunit structure identical with that of serum C1q. Biochem J 
233:451-458. 
235. Thakur V, McMullen MR, Pritchard MT, Nagy LE  (2007) Regulation of macrophage 
activation in alcoholic liver disease. J Gastroenterol Hepatol 22:S53-S56.  
236. Thakur V, Pritchard MT, McMullen MR, Nagy LE (2006) Adiponectin normalizes LPS-
stimulated TNF{alpha} production by rat Kupffer cells after chronic ethanol feeding. Am 
J Physiol Gastrointest Liver Physiol 290:G998-G1007.  
237. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, 
Eggleton P, Hansen S, Holmskov U, Reid KBM, Jensenius JC (1997) A second serine 
protease associated with mannan-binding lectin that activates complement. Nature 
386:506-510. 
238. Thirunavukkarasu C, Watkins SC, Gandhi CR (2006) Mechanisms of endotoxin-
induced NO, IL-6, and TNF-alpha production in activated rat hepatic stellate cells: role 
of p38 MAPK. Hepatology 44:389-398. 
239. Thompson RA and Lachmann PJ (1970) Reactive lysis. the complement-mediated lysis 
of unsensitized cells. I. The characterization of the indicator factor and its identification 
as C7. J Exp Med 131:629-641. 
240. Thurman JM, Holers VM (2006) The central role of the alternative complement pathway 
in human disease. J Immunol 176:1305-1310.  
241. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, 
Giclas PC, Salmon J, Gilkeson G, Holers VM (2005) A novel inhibitor of the alternative 
complement pathway prevents antiphospholipid antibody-induced pregnancy loss in 
mice. Mol Immunol 42:87-97. 
242. Thurman RG (1998) II. Alcoholic liver injury involves activation of Kupffer cells by 
endotoxin. Am J Physiol 275:G605-G611.  
243. Tilg H and Diehl AM (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N 
Engl J Med 343:1467-1476. 
244. Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, Hall BM (2002) 
Attenuation of experimental allergic encephalomyelitis in complement component 6-
deficient rats is associated with reduced complement C9 deposition, P-selectin 
expression, and cellular infiltrate in spinal cords. J Immunol 168:4293-4300. 
245. Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM (2000) A 
lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1 and CREB 
binding protein and p300 is recruited to the tumor necrosis factor a promoter in vivo. 
Mol Cell Biol 20:6084-6094. 
246. Tsukamoto H (2005) Fat paradox in liver disease. Keio J Med 54:190-192. 
247. Turner MW (1996) Mannose-binding lectin: the pluripotent molecule of the innate 
immune system. Immunol Today 17:532-540. 
 67
 248. Uesugi T, Froh M, Arteel GE, Bradford BU, Gabele E (2001) Delivery of Iκβ 
superrepressor gene with adenovirus reduces early alcohol-induced liver injury in rats. 
Hepatology 34:1149-1157. 
249. Uesugi T, Froh M, Arteel GE, Bradford BU, Wheeler MD, Gabele E, Isayama F, 
Thurman RG (2002) Role of lipopolysaccharide-binding protein in early alcohol-induced 
liver injury in mice. J Immunol 168:2963-2969.  
250. Väkevä A, Laurila P, Meri S (1993) Regulation of complement membrane attack 
complex formation in myocardial infarction. Am J Pathol 143:65-75.  
251. Väkevä A, Meri S, Lehto T, Laurila P (1995) Activation of the terminal complement 
cascade in renal infarction. Kidney Int 47:918-926. 
252. Väkevä AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL (1998) Myocardial infarction 
and apoptosis after myocardial ischemia and reperfusion: role of the terminal 
complement components and inhibition by anti-C5 therapy. Circulation 97:2259-2267. 
253. van Beek J, Nicole O, Ali C (2001) Complement anaphylatoxin C3a is selectively 
protective against NMDA-induced neuronal cell death. Neuroreport 12:289-293.  
254. van Dixhoorn MG, Timmerman JJ, Van Gijlswijk-Janssen DJ, Muizert Y, Verweij C, 
Discipio RG, Daha MR (1997) Characterization of complement C6 deficiency in a 
PVG/c rat strain. Clin Exp Immunol 109:387-396. 
255. Wagenaar-Bos IG and Hack CE (2006) Structure and function of C1-inhibitor. Immunol 
Allergy Clin North Am 26:615-632.  
256. Walport MJ (2001) (a) Complement. First of two parts. N Engl J Med 344:1058-1066. 
257. Walport MJ (2001) (b) Complement. Second of two parts. N Engl J Med 344:1140-
1144.  
258. Wan YJ, Morimoto M, Thurman RG, Bojes HK, French SW (1995) Expression of the 
peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic 
liver disease. Life Sci 56:307-317.  
259. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification 
convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 
73:3268-3272. 
260. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC (1995) Studies of group 
B streptococcal infection in mice deficient in complement component C3 or C4 
demonstrate an essential role for complement in both innate and acquired immunity. 
Proc Natl Acad Sci USA 92:11490-11494. 
261. Whaley K and Ruddy S (1976) Modulation of C3b hemolytic activity by a plasma protein 
distinct from C3b inactivator. Science 193:1011-1013. 
262. Wheeler MD, Kono H, Yin M, Rusyn I, Froh M, Connor HD, Mason RP, Samulski RJ 
Thurman RG (2001) Delivery of Cu/Zn-superoxide dismutase gene with adenovirus 
reduces early alcohol-induced liver injury in rats. Gastroenterology 120:1241-1250.  
263. Wheeler MD and Thurman RG (2003) Up-regulation of CD14 in liver due to acute 
ethanol involves oxidant-dependent AP-1 pathway. J Biol Chem 278:8345-8351. 
264. Worner TM and Lieber CS (1985) Perivenular fibrosis as precursor lesion of cirrhosis. 
JAMA 254:627-630. 
265. Wright MS, Sund NJ, Abrahamsen TG (2001) Modulation of C3 gene expression in 
HepG2 human hepatoma cells. Immunol Lett 76:119-123.  
 68
 266. Wurzner R, Joysey VC, Lachmann PJ (1994) Complement component C7. Assessment 
of in vivo synthesis after liver transplantation reveals that hepatocytes do not 
synthesize the majority of human C7. J Immunol 152:4624-4629. 
267. Würzner R, Orren A, Lachmann PJ (1992) Inherited deficiencies of the terminal 
components of human complement. Immunodef Rev 3:123-147.  
268. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ (2003) The fat-derived hormone 
adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin 
Invest 112:91-100.  
269. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, 
Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami 
K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, 
Kadowaki T (2003) Globular adiponectin protected ob/ob mice from diabetes and 
ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468.  
270. Yan J, Vetvicka V, Xia Y, Hanikyrova M, Mayadas TN, Ross GD (2000) Critical role of 
Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or 
soluble beta-glucan. Immunopharmacology 46:39-54. 
271. Yesilova Z, Ozata M, Oktenli C, Bagci S, Ozcan A, Sanisoglu SY, Uygun A, Yaman H, 
Karaeren N, Dagalp K (2005) Increased acylation stimulating protein concentrations in 
nonalcoholic fatty liver disease are associated with insulin resistance. Am J 
Gastroenterol 100:842-849. 
272. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG 
(1999) Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. 
Gastroenterology 117:942-952.  
273. You M and Crabb DW (2004) (a) Molecular mechanisms of alcoholic fatty liver: role of 
sterol regulatory element-binding proteins. Alcohol 34:39-43.  
274. You M and Crabb DW (2004) (b) Recent advances in alcoholic liver disease II. 
Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest 
Liver Physiol 287:G1-G6.   
275. Zipfel PF, Mihlan M, Skerka C (2007) The alternative pathway of complement: a pattern 
recognition system. Adv Exp Med Biol 598:80-92. 
276. Zwaka TP, Torzewski J, Hoeflich A, Dejosez M, Kaiser S, Hombach V, Jehle PM (2003) 
The terminal complement complex inhibits apoptosis in vascular smooth muscle cells 
by activating an autocrine IGF-1 loop. FASEB J 17:1346-1348.  
 
 69
